COVID-19 Treatment AND Vaccine Tracker
Last Updated:
September 16, 2021 2:13 PM
Pacific
FasterCures, a center of the Milken Institute, is currently tracking the development of treatments and vaccines for COVID-19 (coronavirus). This tracker contains an aggregation of publicly-available information from validated sources.
Explore detailed information on each development:
Download a .CSV and explore relationships:
Spreadsheet
Understand definitions of the terms and how our researchers distinguish stages of development:
Glossary
See the race for a
vaccine visualized
Drug developers, academic labs, and other organizations globally are developing many different kinds of medical products to treat COVID-19. Treatments give us tools to help patients while a vaccine is developed. Potential treatments include medicines currently used or studied to treat other diseases (“repurposed” treatments), as well as drugs newly identified or designed to treat COVID-19.
Corvus Pharmaceuticals and Lewis Katz School of Medicine at Temple University
CPI-006
clinical
Phase III trial begun in hospitalized patients
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04734873, NCT04464395
Alexion Pharmaceuticals. TACTIC-R trial
Ultomiris (ravulizumab-cwvz), complement inhibitor
clinical
Phase III recruiting July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04369469, EudraCT 2020-001354-22 (TACTIC-R), ISRCTN11188345, NCT04390464
Assistance Publique - Hopitaux de Paris (Phase II); Alexion (Expanded Access Protocols)
Soliris (eculizumab), complement inhibitor
clinical
Phase II recruiting May 2020. Expanded access protocols
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04288713, NCT04346797, NCT04355494, EudraCT 2020-001246-18
AstraZeneca; ACCORD trial
MEDI3506, monoclonal antibody targeting interleukin 33
clinical
ACCORD Phase II trial to start May 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
UK Government (ACCORD study)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Chronic Obstructive Pulmonary Diesase
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
EudraCT 2020-001736-95 (ACCORD Trial)
BioCon/Equilium
itolizumab, anti-CD6 IgG1 monoclonal antibody
clinical
Phase II open label trial began July 2020; FDA IND cleared for Phase III trial (EQUINOX) Phase 3will not be initiated at this time Nov 2020.
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Graft versus host disease; Lupus nephritis; Plaque psoriasis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04475588, NCT04605926
Bristol Myers Squibb
abatacept (Orencia)
clinical
Developer has intiated and begun to enroll participants in proof-of-concept trial with hospitalized COVID patients
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Operation Warp Speed
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04472494, NCT04477642
CSL Behring
CSL312 (garadacimab)
clinical
A Phase II for safety and efficacy has completed enrollment, results expected Q2 2021
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04409509
CSL Behring / SAb Biotherapeutics
SAB-185, Polyclonal hyperimmune globulin (H-IG)
clinical
Phase I starts early summer 2020; Dosing to start August 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04468958, NCT04469179
CSL Behring Australia
COVID-19 Immunoglobulin, plasma derived
clinical
Phase I/II trials began June 2020; recruitment began Aug 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04548557
Celltrion
CT-P59; Antibodies from recovered COVID-19 patients
clinical
Phase I trial started July 2020; Celltrion beginning commercial production; Korean Ministry of Food and Drug Safety (MFDS) IND application for a Phase II/III trials Sept 2020. Phase II enrollment complete Nov 2020. Approval for special-case use Dec 2020.
Anticipated Next Steps
n/a
Funder
Funder
Unknown
The Korea Health Industry Development Institute
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04525079, NCT04602000, NCT04593641
Celltrion/ University of Oxford/ University Hospitals Birmingham (CATALYST trial)
Remsima (infliximab), anti-TNF antibody
clinical
Phase II trial to start in June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04425538, NCT04734678, EudraCT 2020-001684-89, NCT04922827
Cerecor
CERC-002, anti-LIGHT monoclonal antibody
clinical
Phase II recruiting July 2020, top line data expected 4Q 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Pediatric Crohn's Disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04412057
CytoDyn
leronlimab (PRO 140), a CCR5 antagonist
clinical
Phase II trial interim results released July 2020; Phase II trial (mild/moderate) met enrollment in June 2020; Phase IIb/III trial (severe) ongoing June 2020; individual expanded access. Enrollment completed Dec 2020.
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Treatment of HIV/AIDS, Graft versus Host Disease, Non-Alcoholic Steatohepatitis, and numerous cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04343651, NCT04347239, NCT04901676, NCT04901676, NCT040901689
EUSA Pharma / The Papa Giovanni XXII Hospital; University Hospital, Ghent; Fundacion Clinic per a la Recerca Biomédica
Sylvant (siltuximab), interleukin-6 targeted monoclonal
clinical
FDA approves Phase III trial in hospitalized patients in July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04322188, NCT04330638, NCT04329650, EudraCT 2020-001500-41, EudraCT 2020-001854-23, EudraCT 2020-001413-20, NCT04486521
Edesa Biotech/ Light Chain Bioscience (NovImmune)
EB05, non-steroidal anti-inflammatory molecule (sPLA2 inhibitor)
clinical
Phase I/II not yet recruiting July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
ARDS
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Phase II trials FDA to begin Oct 2020; NCT04401475
Eli Lilly
LY3127804, anti-Angiopoietin 2 (Ang2) antibody
clinical
Phase II trial recruiting July 2020; Phase II study ended Oct 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04342897
Eli Lilly/AbCellera (NIH Vaccines Research Center)/Takeda
LY-CoV555 antibody from recovered patients
clinical
Phase II trial recruiting July 2020; Phase I started June 2020; results expected end of June 2020; FDA IND application for EUA requested Oct 2020; FDA EUA approved Nov 2020. Interim authorization from Health Canada Nov 2020. Doses purchased by US, Dec 2020.
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Defense Advanced Research Projects Agency/ Government of Canada (ISED Strategic Innovation Fund)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04411628, NCT04427501, NCT04497987, NCT04441931
Emergent BioSolutions/ National Institute of Allergy and Infectious Diseases (NIAID)/ Mt Sinai Health System/ ImmunoTek Bio Centers
Polyclonal hyperimmune globulin (H-IG)
clinical
Phase II trials begin ~August 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Same human hyperimmune platform as FDA-approved anthrax treatment (Anthrasil) and smallpox vaccine complications (VIGIV) were developed
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04661839
GC Pharma/ Korea National Institute of Health
GC5131A, plasma derived therapy
clinical
Phase II/III to start in July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
GSK
otilimab, anti-granulocyte macrophase colony-stimulating factor (GM-CSF) antibody
clinical
Phase II recruiting June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
To treat rheumatoid arthritis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04376684
Generation Bio/ Vir Biotechnology
Non-viral gene therapy to produce monoclonal antibodies
clinical
Phase I trials for IN01 vaccine treatment in ex-COVID patients began Oct 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04537130
Grifols
Gamunex-C, contains anti-SARS-CoV-2 polyclonal antibodies from recovered plasma donors
clinical
Trial to begin Feb 2021 in Spain
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04480424
Grifols
Polyclonal hyperimmune globulin (H-IG)
clinical
Phase I trial expected to start July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04432324, NCT04480424
Harbour BioMed / Erasmus MC / Utrecht University / Mount Sinai Health System / AbbVie
Antibody 47D11
clinical
Phase I clinical trial initiated Dec 2020. Licensed for clinical development Dec 2020.
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04644120
Humanigen Inc./ Catalent Biologics
lenzilumab, anti-granulocyte-macrophage colony stimulating factor antibody
clinical
Data on first clinical use released June 2020; Phase III trial ongoing July 2020/Dosing began Oct 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Prevent cytokine storm with CAR-T cancer therapy; prevention/treatment of acute graft versus host disease; chronic myelomonocytic leukemia; eosinophilic asthma
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04351152
I-Mab Biopharma
TJM2 (TJ003234), anti-granulocyte-macrophage colony stimulating factor antibody
clinical
Interim Phase I/II data released June 2020, part 2 of the study to start June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04341116
I-SPY COVID trial (Omeros)
Narsoplimab (IV administered mannan-binding lectin-associated serine protease-2 (MASP-2) pathway inhibitor IgG4 antibody)
clinical
Data from compassionate use in Italy released Nov 2020; first patient dosed in I-SPY trial March 2021
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Quantum Leap Healthcare Collaborative
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) (pending FDA approval)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04488081
Implicit Bioscience
IC14, recombinant chimeric anti-CD14 monoclonal antibody
clinical
Phase II not yet recruiting July 2020; Expanded access protocols
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Acute Respiratory Distress Syndrome
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04346277, NCT04391309
InflaRx N.V.
IFX-1, anti-C5a antibody
clinical
Phase III trial to begin fall 2020; Phase II topline results reported June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
To treat various inflammatory conditions including hidradenitis suppurativa, ANCA-associated vasculitis, and pyoderma gangraenosum
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04333420, EudraCT 2020-001335-28
Junshi Biosciences/ Eli Lilly/ Lonza/ AbCellera
JS016 antibody candidate (LY-CoV016 + LY-CoV555)
clinical
Phase I trial in China started June 2020; trial in US to start 2H 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04441918, NCT04780321, NCT04931238
Kamada/ Kedrion Biopharma/ Columbia University Irving Medical Center
Antibodies from recovered COVID-19 patients
clinical
Individual Expanded Access use in Israel started in June 2020; Phase I/II in hospitalized patients in Israel to start 3Q 2020; Will talk to FDA in 3Q 2020; enrollment completed Sept 2020 in Israel
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Kiniksa/ Cleveland Clinic/ Ospedale San Raffaele
mavrilimumab, anti-granulocyte-macrophase colony-stimunlating factor receptor-alpha monoclonal antibody
clinical
Phase II trial recruiting June 2020; Case reports published June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Giant cell arteritis (GCA); rheumatoid arthritis; large B-cell lymphoma (with Yescarta)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04399980, NCT04397497, NCT04447469, NCT04463004, EudraCT 2020-001795-15
Multiple global research sponsors, including: New York State Department of Health; Johns Hopkins University; the Feinstein Institutes; RECOVERY trial
Convalescent plasma (blood plasma from recovered patients)
clinical
Mayo Clinic and Houston Methodist trial results published June 2020, other trials ongoing; FDA issued Emergency Use Authorization on Aug 23, 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Bloomberg Philantropies and the State of Maryland (to Johns Hopkins University)/ Biomedical Advanced Research and Development Authority (BARDA) (to Mayo Clinic), Department of Defense (DoD)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Many expanded access, observational, patient registry, plasma collection, prevention, and other studies listed in clinicaltrials.gov, including: NCT04321421, NCT04292340, NCT04316728, NCT04338360, NCT04345289, NCT04349410, NCT04346589, NCT04333251, NCT04361253, NCT04323800, NCT04359810, NCT04362176, NCT04354831, NCT04360486, NCT04321421, NCT04441424, NCT04460547, NCT04381936 (RECOVERY), EudraCT 2020-001310-38, ISRCTN67000769 (REMAP-CAP), EudraCT 2015-002340-14 (REMAP-CAP), NCT02735707 (MJM Bonten), NCT04467151, NCT04442191, NCT04456413, NCT04438057, NCT04377568, NCT04418518, NCT04408040, NCT04397757, NCT04390503, NCT04385199, NCT04421404, NCT04364737, NCT04344535, NCT04355767, NCT04373460, NCT04377672, NCT04528368, NCT04497324
Multiple global research sponsors; Octapharma USA/ Sharp Memorial Hospital; Grifols
Octagam; intravenous Immunoglobulin (IVIG)
clinical
Octapharma released topline results from retrospective study July 2020; Phase III study ongoing July 2020; Phase 1/2 trials began
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04261426, NCT04264858, NCT04350580, NCT04400058, NCT04411667, EudraCT 2020-002482-34, NCT04480424, NCT04432324, 2020-001890-56, NCT04521309
Novartis; other research sponsors
Ilaris (canakinumab), interleukin-1beta blocker
clinical
Novartis Phase III to start and trial top-line results expected late summer 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04348448, NCT04362813, NCT04365153, EudraCT 2020-001854-23, NCT04476706
Numerous trials with Chinese research sponsors
PD-1 blocking antibody; Thymosin
clinical
Phase II study not yet recruiting
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04268537, ChiCTR2000030028
Numerous trials with Chinese research sponsors; Roche
Avastin (bevacizumab), vascular endothelial growth factor inhibitor
clinical
Phase II/III studies recruiting April 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04275414, NCT04305106, NCT04344782, EudraCT 2020-001246-18
Numerous trials with global research sponsors; Roche; REMAP-CAP; RECOVERY
Actemra (tocilizumab), interleukin-6 receptor antagonist
clinical
Initial Roche studies could be completed May or June 2020; Phase II open-label study in Italy active (April 2020), Phase III Roche global trial enrolling May 2020, Roche trial (+ remdesivir) to start June 2020; ; Phase 3 EMPACTA Trial (tocilizumab + placebo); HEPMAB (Actemra + Heparin) Phase 3 trials begin Oct 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04317092, NCT04320615, NCT04310228, ChiCTR2000030894, NCT04306705, ChiCTR2000030442, ChiCTR2000029765, NCT04322773, NCT04345445, NCT04331795, NCT04332094, NCT04346355, NCT04359667, NCT04332913, NCT04335071, NCT04356937, NCT04361032, NCT04315480, NCT04339712, NCT04333914, NCT04361552, NCT04330638, NCT04331808, NCT02735707, NCT04349410, NCT04363736, NCT04372186, NCT04363853, EudraCT 2020-001754-21, EudraCT 2020-001500-41, EudraCT 2020-001246-18, EudraCT 2020-001039-29, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT 2020-001854-23, NCT04381936 (RECOVERY), NCT04409262, EudraCT 2020-001903-17, NCT04560205, NCT04577534, NCT04600141
Regeneron/ NIAID
Antibody combination REGN-COV2 (REGN10933+REGN10987) against the spike protein
clinical
Joined Operation Warp Speed in July 2020; Phase III prevention trial with NIAID starts July 2020; Phase 2 stage of 1/2/3 treatment trial started July 2020; Phase 3 starts Aug 2020; compassionate use/expanded access requested Oct 2020. FDA Emergency Use Authorization Nov 2020.
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Defense
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04425629, NCT04426695, NCT04452318, NCT04617535, NCT04992273, NCT04852978
Roivant Sciences
Gimsilumab, anti-granulocyte-macrophage colony stimulating factor monoclonal
clinical
Phase II study started in April 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04351243
Sorrento Therapeutics/ Mount Sinai Health System/ Columbia University
COVI-SHIELD/COVI-TRACE/COVI-GUARD antibody cocktail that binds to three different epitopes
clinical
Start Phase II trial Q3 2020; FDA cleared for Phase I for COVI-GUARD (STI-1499) in hospitalized COVID-19 patients. WITHDRAWN.
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04454398
Staidson/ Pivotal
BDB-001, monocloncal anti-C5a antibody
clinical
Phase II/III trials began Jul 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
EudraCT 2020-001671-32, NCT04449588
Swedish Orphan Biovitrum
Gamifant (emapalumab), anti-interferon gamma antibody
clinical
Phase II/III recruiting April 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04324021
Tang-Du Hospital
meplazumab, anti-CD147 antibody
clinical
Results released July 2020; Phase II/III efficacy trials begin Oct 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Chinese National Science and Technology Major Project
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04275245, NCT04586153
Tsinghua University/ Third People's Hospital of Shenzhen/ Brii Biosciences
BRII-196 and BRII-198, Antibodies from recovered COVID-19 patients
clinical
Phase I trials recruiting July 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04479644, NCT04479631, NCT04691180, NCT04770467
Tychan/ SingHealth Investigational Medicine Unit
TY027, monoclonal antibody targeting SARS-CoV-2
clinical
Phase I started June 2020; efficacy data expected 3Q 2020. Phase III began Dec 2020.
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04429529, NCT04649515
University of Hong Kong (BMS)
Opdivo (nivolumab), PD-1 blocking antibody
clinical
Phase II study not yet recruiting
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04356508, NCT04333914, NCT04405271, NCT04343144
Vanderbilt Vaccine Center/ AstraZeneca/ IDBiologics
Combo of two antibodies (AZD7442)
clinical
Phase I trial began August 2020; Phase III trial began Nov 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Defense Advanced Research Projects Agency/ Dolly Parton/ Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04507256, NCT04625725
Various global research sponsors/ Grifols/ Emergent BioSolutions, CSL Behring and Takeda
Prolastin, alpha-1 anti-trypsin antibody
clinical
Phase II trial recruiting July 2020; Phase III trials began Oct 2020 (ITAC Trial)
Anticipated Next Steps
n/a
Funder
Funder
Unknown
National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
EudraCT 2020-001391-15, NCT04385836, NCT04495101, NCT04547140, NCT04799873
Vir Biotechnology/ GSK/ Samsung/ WuXi Biologics/ Biogen
VIR-7831 and VIR-7832, antibodies from recovered SARS patients
clinical
Start Phase II ~July-September 2020; Dosing began Aug 2020; Phase 3 results and endpoints expect Jan 2021; Submitted for EUA May 2021
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04545060, NCT04913675, NCT04913675, NCT04779879, NCT04746183, NCT04988152
Abcore
Single domain antibodies (sdAbs), engineered monoclonal antibody derived from camelids
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Ablexis / AlivaMab Discovery Services / Berkeley Lights Collaborate
Antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Adagio Therapeutics
Antibodies binding to a piece of the spike protein found on multiple coronaviruses including SARS-CoV-2, ADG20
pre-clinical
Phase I trial expected to start by early 2021
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04805671, NCT04859517
Alliance - Proteona/ NMI/ NUS Enterprise/10X Genomics/ NovogeneAIT/ Twist Bioscience/ University Hospitals/ German Cancer Research Center, Heidelberg University Hospital/ Tübingen University Hospital/ NovogeneAIT
Antibody for immunocompromised patients
pre-clinical
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Amgen/ Adaptive Biotechnologies
Antibodies from recovered COVID-19 patients
pre-clinical
Phase I trial expected to start ~October 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
AstraZeneca / US Army Medical Research Institute of Infectious Diseases (USAMRIID)/ University of Maryland School of Medicine
Antibodies targeting the S protein from convalescent serum, humanized mice, and phage display
pre-clinical
Phase I/II trials begin in summer 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Atreca / BeiGene / IGM Biosciences/ Singlomics
Novel IgM and IgA antibodies
pre-clinical
Phase I/II trials to begin in Oct 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04511949
Celltrion
Super-antibody or antibody cocktail to target potential mutations of SARS-CoV-2
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Centivax (Distributed Bio)
Antibody
pre-clinical
Released hamster study results in June 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Chelsea and Westminster Hospital, Imperial College London
Antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
UK Government
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
CoVIg-19 Plasma Alliance (Takeda, CSL Behring, Biotest AG, Bio Products Laboratory, LFB, and Octapharma, ADMA Biologics, BioPharma Plasma, GC Pharma, Sanquin)/Gates Foundation/ NIAID/ Microsoft
Polyclonal hyperimmune globulin (H-IG), unbranded (TAK-888)
pre-clinical
Phase I trials start in summer 2020; To patients between December 2020 and December 2021; Phase III first patient enrolled, Oct 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Cologne University Hospital/ German Center for Infection Research/ Boehringer Ingelheim
BI 767551, Antibodies from recovered COVID-19 patients
pre-clinical
Clinical trials to start in 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04631705, NCT04822701, NCT04894474, EudraCT 2020-005588, EudraCT 2021-000408-39-29,
Columbia University Irving Medical Center; IAVI and Serum Research Institute India
Mix of neutralizing antibodies isolated from recovered COVID-19 patients
pre-clinical
Recruiting Dec 2020.
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
NCT04606407, NCT04390503, NCT04359810
Costa Rican Social Security Fund (CCSS)/ The University of Costa Rica (UCR)/ Clodomiro Picado Institute
Antibodies from recovered COVID-19 patients
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Edesa Biotech / Light Chain Bioscience (NovImmune)
Monocloncal antibodies, CXC10 antagonist
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Eli Lilly/ Sanford Burnham Prebys Medical Discovery Institute
Neutralizing antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Emergent BioSolutions
Horse plasma product (COVID-EIG)
pre-clinical
Phase II trials begin ~August 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Same equine hyperimmune platform as FDA-approved botulism anti-toxin (BAT) is produced
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Fab'entech
Polyclonal antibodies
pre-clinical
Expected to begin Phase I/II trials in early 2021
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
FairJourney Biologics / Iontas
Antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
GigaGen
rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin), polyclonal antibodies
pre-clinical
Phase I trial expected to start early 2021
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Grifols
Antibodies from recovered COVID-19 patients
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
IGY Life Sciences/ MMS Holdings/ Canadian Government National Microbiology Lab
IgY-110, anti-CoV-2 antibody (nasal spary application)
pre-clinical
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
ImmunoPrecise Antibodies
Monoclonal antibody cocktail
pre-clinical
Lead candidates identified June 2020, pre-clinical studies to start summer 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
North Dakota Bioscience Innovation Grant
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Immunome
Novel biosynthetic convalescent plasma (BCP)
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Department of Defense (DoD)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Innovent Biologics
Antibodies from recovered COVID-19 patients
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Ligand Pharmaceuticals
Antibodies (OmniChicken platform)
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Ligand Pharmaceuticals
Antibodies (OmniRat platform)
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Medicago / Laval University's Infectious Disease Research Centre
Antibodies
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Canadian Institutes for Health Research (CIHR)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Prellis Biologics
Antibodies
pre-clinical
Phase I trial could begin as early as Sept 2020
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Public Health England (Stuart Dowall)
Purified ovine immunoglobulin from immunized sheep
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
UK Government
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Rosalind Franklin Institute/ Oxford University/ Diamond Light Source/ Public Health England
Nanobodies from Llamas
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Tiziana Life Sciences
TZLS-501, an anti-interleukin-6 receptor monoclonal antibody (inhalation technology in development-Foralumab anti-CD3 monoclonal antibody)
pre-clinical
Plan to initiate Phase I in Q1 2021
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
University of Texas at Austin/ US National Institutes of Health/ Ghent University
Linked nanobody antibody
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Virna Therapeutics/ University of Toronto
Neutralizing antibodies
pre-clinical
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Xbiotech/ BioBridge Global
Antibodies from recovered COVID-19 patients
pre-clinical
Unknown
Anticipated Next Steps
n/a
Funder
Funder
Unknown
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
Unknown
Developer / Researcher
Product Description
PHASE
Next Steps
Pfizer
PF-07321332
clinical
Phase I trial in healthy patients
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04756531, NCT04909853, NCT04960202, NCT04962022, NCT05011513
Acer Therapeutics / US National Center for Advancing Translational Sciences (NCATS)
emetine hydrochloride
clinical
Phase II/III to start in Q3 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
To treat viral hepatitis and varicella-virus
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Ansun Biopharma/ Renmin Hospital of Wuhan University
DAS181, recombinant sialidase (nebulized)
clinical
Individual patient expanded access finding released in May 2020; Phase II/III started enrolling in May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of lower respiratory tract parainfluenza virus infections and severe influenza infections
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT03808922, NCT04354389, NCT04298060, NCT04324489, NCT04460547
Ascletis / Chinese research sponsors
Ganovo (danoprevir), hepatitis C virus NS3 protease inhibitor; ritonavir; interferon, approved in China to treat Hepatitis C
clinical
Small open label trial completed and results released in March 2020; Larger open label trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of Hepatitis C
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04291729 NCT04345276
Ascletis/ Chinese research sponsors
ASC09, HIV protease inhibitor
clinical
Phase III trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of HIV/AIDS
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04261907 NCT04261270
Atea Pharmaceuticals/ Roche
AT-527, oral purine nucleotide prodrug
clinical
Phase II trial to start May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of Hepatitis C infections
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04396106
Bausch Health
Virazole (ribavirin for inhalation solution)
clinical
Phase II recruiting May 2020; Individual patient expanded access
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04356677, NCT04460443, NCT04392427, NCT04276688, NCT04551768
Beech Tree Labs
BTL-tml
clinical
FDA cleared trial July 2020, trial to start July/Aug 2020 with results available Fall 2020; Has been used in 36 patients anecdotally; Phase II trial started August 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of herpes virus infections
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04522830
BioCryst Pharmaceuticals
galidesivir
clinical
Phase Ib recruiting May 2020
n/a
Funder
Funder
n/a
National Institute of Allergy and Infectious Diseases (NIAID)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of yellow fever
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT03891420
Bukwang Pharm
Levovir (clevudine)
clinical
Phase II trial not yet recruiting
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04347915
Fujifilm Toyama Chemical/ Zhejiang Hisun Pharmaceuticals/ numerous trials with global research sponsors/ Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School/ Glenmark Pharmaceuticals
Favilavir/ Favipiravir/ T-705/ Avigan, licensed in Japan to treat influenza
clinical
Fuijfilm trial initial results released July 2020; Glenmark Phase III trial in India top-line results released July 2020 (Glenmark)
n/a
Funder
Funder
n/a
Life Arc (FLARE trial; PIONEER trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04303299, NCT04310228, ChiCTR2000029548, ChiCTR2000029496, ChiCTR2000029544, ChiCTR2000030254, NCT04336904, NCT04333589, NCT04345419, EudraCT 2020-001435-27, NCT04356495, NCT04425460, NCT04373733, EudraCT 2020-001449-38, EudraCT 2020-001528-32, EudraCT 2020-001904-41, NCT04468087, NCT04376814, NCT04411433, NCT04445467, NCT04402203, NCT04392973, NCT04349241, NCT04346628, NCT04448119, NCT04475991, NCT04358549, NCT04434248, NCT04359615, NCT04464408, NCT04387760, NCT04474457, NCT04351295, EudraCT Number: 2020-002106-68,  NCT04529499, NCT04558463
Gilead; World Health Organization SOLIDARITY trial; National Institute of Allergy and Infectious Diseases (NIAID)'s Adaptive COVID-19 Treatment Trial; Feinstein Institutes; I-SPY COVID
remdesivir, nucleotide analog
clinical
Gilead releases additional data Phase III trial on July 10, 2020; Gilead's Phase Ia trial of inhalant version started July 2020; EU grants conditional authorization July 3, 2020; Gilead starting Phase II/III trial in pediatric patients in June 2020; FDA issued an Emergency Use Authorization on May 1, 2020; Expanded EUA access Aug 2020, Phase I trial in pregnant & non-pregnant women Oct 2020; Phase II Trials Remdesivir + Lenzilumab Oct 2020; ; ACTV-1 IM adaptive remdesivir trial begins Oct 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of Ebola
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04257656, NCT04252664, NCT04292730, NCT04292899, NCT04280705, EudraCT 2020-000936-23, NCT04315948, NCT04302766, NCT04323761, NCT04349410, NCT04401579, EudraCT 2020-001052-18, ISRCTN83971151 (Solidarity), EudraCT 2020-001366-11 (Solidarity Spain), EudraCT 2020-000982-18 (Norway Solidarity), EudraCT 2020-001784-88 (Finland Solidarity), EudraCT 2020-001549-38 (Solidarity Germany), NCT04330690, NCT04431453, NCT04409262, NCT04321616, EudraCT 2020-001448-24, NCT04365764, NCT04410354, NCT04365725, NCT04480333 (inhaled remdesevir + neurosivir), NCT04488081, EudraCT 2020-000841-15, EudraCT 2020-001453-49, EudraCT 2020-000842-32, EudraCT 2020-001803-17, EudraCT 2020-002060-31, NCT04501978, NCT04582266, NCT04583969, NCT04583956
Global hospital testing (AbbVie); World Health Organization SOLIDARITY trial (studying lopinavir/ ritonavir with and without interferon beta); University of Oxford RECOVERY trial; REMAP-CAP global trial; Univ. of College, London
Kaletra/Aluvia (lopinavir/ritonavir), HIV-1 protease inhibitor
clinical
WHO discontinues lopinavir-ritonavir arm in the SOLIDARITY trial July 2020; RECOVERY trial results released June 2020 and stopped that trial arm
n/a
Funder
Funder
n/a
UK Government (University of Oxford RECOVERY trial); Life Arc (FLARE trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04303299, NCT04255017, ChiCTR2000029548, ChiCTR2000029539, EudraCT 2020-000936-23, NCT04307693, NCT04315948, NCT04252885, NCT04276688, NCT02735707, NCT04321993, 2020-001113-21, NCT04286503, NCT04328012, NCT04346147, NCT04350671, NCT04466241, EudraCT 2020-001825-29, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT number: 2020-001321-31, ISRCTN83971151 (Solidarity), EudraCT 2020-001366-11 (Solidarity Spain), EudraCT 2020-001528-32, EudraCT 2020-001723-13, EudraCT 2020-000982-18 (Norway Solidarity), EudraCT 2020-001549-38 (Solidarity Germany), NCT04381936 (RECOVERY), NCT04386070, NCT04372628, NCT04330690, EudraCT 2020-001448-24, NCT04435587, NCT04425382, NCT04376814, EudraCT 2020-001605-23, NCT04251871, NCT04275388, NCT04521400, NCT04499677
Hospital Universitario Infanta Leonor/ Viiv Healthcare; Hospital General de México Dr. Eduardo Liceaga; Rhode Island Hospital
Selzentry (maraviroc), a CCR5 co-receptor antagonist
clinical
Phase II trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04475991, NCT04441385, NCT04435522, NCT04710199
Hospital do Coracao
Sofusbuvir
clinical
Phase II/III trial not yet recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04468087, NCT04561063, NCT04729153, NCT04773756
Multiple global research sponsors
Prezcobix (darunavir, HIV-1 protease inhibitor/cobicistat, CYP3A inhibitor)
clinical
Phase III trials recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000029541, NCT04252274, NCT04303299, NCT04304053, EudraCT 2020-001528-32, NCT04435587, NCT04425382
Multiple global research sponsors
Arbidol (umifenovir), licensed in Russia and China for treatment of respiratory viral infections
clinical
Phase IV trials recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04252885, NCT04350684, NCT04286503, NCT04260594, NCT04273763
National Institute of Allergy and Infectious Disease (NIAID)/University of Minnesota
Hyperimmune immunoglobulin (hIVIG) + Remdesivir
clinical
Phase III adaptive trial (ITAC) began Oct 2020; Phase III recruitment began Oct 2020
n/a
Funder
Funder
n/a
National Institute of Allergy and Infectious Diseases (NIAID); The International Network for Strategic Initiatives in Global HIV Trials
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04546581, EudraCT 2020-002542-16, NCT04910269
NeuroActiva
Neurosivir (NA-831)
clinical
Phase II/III trial recruiting July 2020 (neurosivir); Phase I trial recruiting July 2020 (inhaled remdesevir + neurosivir)
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Alzheimer's disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04452565, NCT04480333 (inhaled remdesevir + neurosivir), NCT04540185
Pfizer
PF-07304814
clinical
Phase Ib trial in hospitalized COVID patients
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04535167
Plan Nacional sobre el Sida
Truvada (emtricitabine and tenofovir, both HIV-1 nucleoside analog reverse transcriptase inhibitors)
clinical
Phase III trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000029468, NCT04334928, NCT04405271
Ridgeback Biotherapeutics / Drug Innovation Ventures at Emory (DRIVE)/ Merck
EIDD-2801, oral ribonucleoside analog
clinical
Phase III trial started August 2021
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04405739, NCT04405570, NCT04392219
Roche; REMAP-CAP global trial
Tamiflu (oseltamivir), neuraminidase inhibitor
clinical
REMAP-CAP trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04303299, NCT04255017, NCT04261270, NCT02735707, NCT04338698, NCT04371601, EudraCT 2015-002340-14 (REMAP-CAP), NCT04457609
Various global research sponsors/University of Liverpool/Obafemi Awolowo University
Atazanavir, protease inhibitor
clinical
Phase II trial (Nitazoxanide + atazanavir/ritonavir) began Oct 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04459286, NCT04468087, NCT04452565, EudraCT 2020-005919-51
Various global research sponsors
Daklinza (daclatasvir), hepatitis C virus (HCV) NS5A inhibitor
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04443725, NCT04468087, NCT04535869, NCT04561063, NCT04729153
Agastiya Biotech
AB001
pre-clinical
Phase I to start in 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Anivive Lifesciences
GC376, protease inhibitor
pre-clinical
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Cidara Therapeutics
antiviral Fc conjugates
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Cocrystal Pharma
Antiviral compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ISR Immune System Regulation
ISR-50
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Iaterion, Inc.
AVIM1 (MyD88 inhibitor, S1/S2 site inhibitor, and entry inhibitor composed of three molecules: IATAV049, IATAV051, IATAV052)
pre-clinical
 In vitro models found no cytotoxicity; expected to enter clinical trials early 2021
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
SCORE consortium (universities of Aix-Marseille, Leuven, Utrecht, Bern, and Lubeck), the Helmholtz Centre for Infection Research, and Janssen Pharmaceutica NV
Antiviral drug combinations
pre-clinical
Unknown
n/a
Funder
Funder
n/a
EU Commission (Horizon 2020 Program)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Selva Therapeutics 
SLV213, cysteine protease inhibitor
pre-clinical
FDA IND approved for Phase I trial; First patient dosed Nov 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04431414, NCT04403880, NCT04843787
Stanford University/ US Department of Energy's Lawrence Berkeley National Laboratory
Prophylactic antiviral CRISPR in human cells (PAC-MAN)
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ViralClear Pharmaceuticals
Vicromax, broad spectrum antiviral
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
AgenTus Therapeutics (Agenus) 
AgenT-797, allogeneic invariant natural killer T cells
clinical
FDA cleared Phase I trial June 2020; First patient dosed Nov 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AlloVir / Baylor College of Medicine
Allogeneic T-cell therapies
clinical
Phase I not yet recruiting July 2020; ; FDA IND approved Sept 2020; Dosing began Nov 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04401410
Aspire Health Science
ACT-20, allogeneic cell preparation of mesenchymal stem cells from umbilical cord tissue
clinical
Phase I/II trial FDA cleared June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04398303
Athersys / The University of Texas Health Science Center at Houston
MultiStem, bone marrow stem cells
clinical
Phase II/III trial recruiting May 2020
n/a
Funder
Funder
n/a
Medical Technology Enterprise Consortium (MTEC)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute Respiratory Distress Syndrome; Stroke
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04367077
Caladrius Biosciences
CLBS119, autologous peripheral blood-derived CD34+ cell therapy
clinical
Phase II trial expected to start Q3 2020; Phase I open label trial began Oct 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04522817
Capricor Inc.
CAP-1002, allogenic cardiosphere-derived cells
clinical
Expanded access protocol trial ongoing May 2020; FDA approved IND in August 2020 for Phase II trial
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Duchenne muscular dystrophy
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04338347
Cellenkos
CK0802, allogeneic cell therapy containing T-regulatory cells from umbilical cord blood processed to express lung homing markers on the cell surface
clinical
Two case reports released July 2020; FDA cleared Phase I trial July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04468971
Celltex
Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs) and allogeneic MSCs
clinical
FDA approves Phase II trial June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Injuries, Pain, and Autoimmune, Vascular and Other Disease, including Inflammatory lung conditions, pneumonia, and chronic obstructive pulmonary disease (COPD)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04428801, NCT04352803
Celularity/ Lung Biotechnology PBC/ California Institute for Regnerative Medicine (CIRM)
CYNK-001, allogeneic, natural killer cell therapy
clinical
Phase I/II study recruiting August 2020; Dosing began for Phase I/II Phase; I/II evaluation complete Dec 2020.
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various hematologic cancers and solid tumors
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04365101
Cynata Therapeutics
CYP-001 (Cymerus MSC), Mesenchymal stem cells
clinical
Phase II to start in July 2020 in Australia
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04537351
Daewoong
DWP710, DW-MSC, a mesenchymal stem cell therapy
clinical
Phase I trial started July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04535856
Duke-NUS Medical School; various hospitals (Singapore)
Chimeric antigen receptors (CAR)/T cell receptors (TCR)-T cell therapy
clinical
Phase I/II open label trials began in July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04457726
Enlivex Therapeutics
Allocetra, early apopototic cells
clinical
Phase II trial started May 2020; First patient dosed in phase II trials in Israel
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Sepsis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04659304, NCT04922957
Hope Biosciences/Daewoong Pharmaceutical Co. LTD/ Other global research sponsors
Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)
clinical
Phase II started in April 2020, Phase I efficacy trial began Aug 2020
n/a
Funder
Funder
n/a
Hope Biosciences Stem Cell Research Foundation
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Rheumatoid arthritis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04348435, NCT04349631, NCT04362189, NCT04535856
ImmunityBio / NantKwest / Be The Match BioTherapies
Bone marrow-derived allogenic mesenchymal stem cells (BM-Allo-MSC)
clinical
Phase Ib trial to start June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04397796
Lattice Biologics
AmnioBoost, concentrated allogeneic MSCs and cytokines derived from amniotic fluid
clinical
Phase I enrolling April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Mesoblast/ Cardiothoracic Surgical Trials Network
Ryoncil (remestemcel-L), allogenic mesenchymal stem cells
clinical
Expanded access protocol started for children July 2020; Phase II/III trial started May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Graft versus host disease and other rare diseases, chronic obstructive pulmonary disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04366830, NCT04371393, NCT04456439
Naturecell Co. LTD
Astrostem-V, Allogenic, adipose-derived mesenchymal stem cells (HB-adMSCs)
clinical
Phase I/IIa trial approved by South Korea Ministry of Food and Drug Safety in March 2020; Phase I/II efficacy trial to start Dec 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04486001, NCT04527224
Numerous trials with global research sponsors/ MD Anderson Cancer Center
Mesenchymal stem cells
clinical
Phase I trials ongoing May 2020; Phase I/II trials recruiting May 2020; Phase II/III trial recruiting May 2020; Phase 2 trial enrollment Sept 2020-EXIT COVID-19
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
30 trials listed in clinicaltrials.gov, including: ChiCTR2000029990, NCT04315987, NCT04302519, NCT04288102, NCT04313322, NCT04273646, NCT04371601, NCT04315987, NCT04252118, NCT04336254, NCT04339660, NCT04371601, NCT04366063, NCT04467047, NCT04461925, NCT04444271, NCT04493242, NCT04565665
Pluristem Therapeutics/ BIH Center for Regenerative Therapy/ Berlin Center for Advanced Therapies
PLX cell product, placenta-based cell therapy
clinical
Phase II trial recruiting July 2020; Results from individual patient expanded access released in April/May 2020; Phase II trials began Nov 2020. PLI study terminated Dec 2020.
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various conditions
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04389450, NCT04614025
Red de Terapia Celular (TerCel)
MSV_allo, allogenic mesenchymal stem cells
clinical
Phase I/II trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04361942, EudraCT 2020-001682-36
Sentien Biotechnologies
SBI-101, biologic/device combo product with allogeneic mesenchymal stem cells and a phasmapheresis device
clinical
Phase I/II trial to start August 2020 Phase I/II now recruiting Nov 2020.
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04445220
Therapeutic Solutions International
StemVacs, universal donor natural killer cell-based therapy
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Cancer
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Trustem Cell Therapy
Umbilical cord-derived mesenchymal stem cells
clinical
Phase II trial to start in Columbia in July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04429763
Vitro Biopharma/ Global Institute of Stem Cell Therapy and Research
AlloRx stem cells, umbilical cord mesenchyma stem cell therapy
clinical
Individual expanded access results released July 2020; IND submitted to FDA April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Inflammatory conditions
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AgeX Therapeutics/ ImStem Biotechnology
IMS001, human embryonic stem cell-derived mesenchymal stem cells (hES-MSC)
pre-clinical
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Baylx, Inc. 
BX-U001, allogeneic umbilical cord derived mesenchymal stem cell (hUC-MSC)
pre-clinical
FDA cleared Investigational New Drug (IND) application for BX-U001
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Rheumatoid arthritis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BioCardia
BCDA-4, bone marrow-derived allogenic neurokinin-1 receptor positive mesenchymal stem cells
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CAR-T (Shanghai) Biotechnology
Dental pulp-derived mesenchymal stem cells
pre-clinical
Phase I/II trials began April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04336254, NCT04302519
Citius/Novellus
NoveCite cells (NC-MSCs), mesenchymal stem cells derived from a single donor's fibroblasts
pre-clinical
Phase I trial to start by end of 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
GC LabCell / KLEO Pharmaceuticals
Natural killer cell-based therapy
pre-clinical
Begin Phase I by end of 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ImmunityBio / NantKwest
haNK, natural killer cells
pre-clinical
Pre-IND submitted to FDA in May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Kangstem Biotech
Furestem RA, allogenic umbilical cord blood-derived stem cell therapy
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Regeneris Medical
Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs)
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
SMSbiotech
Small mobile stem (SMS) cells
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
ALung Technologies
Hemolung Respiratory Assist System
clinical
Phase III (COViNOX Study) Trials began Summer/Fall 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute Exacerbation of Chronic Obstructive Pulmonary Disease; Acute Respiratory Distress Syndrome (ARDS)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT03255057
Abiomed
Impella RP heart pump
clinical
FDA issued an Emergency Use Authorization for Impella heart pumps in COVID-19 therapy on May 29, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Baxter
Oxiris Blood Purification Filter
clinical
FDA issued an Emergency Use Authorization on April 23, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04478539
Bellerophon; Ohio State University Wexner Medical Center
INOpulse
clinical
Phase III trial began July 2020; Expanded access trial ended July 2020; Phase III (COViNOX Study) Trials began Summer/Fall 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04398290, NCT04358588 (Expanded access), NCT04421508, EudraCT 2020-002394-94
Beyond Air Ltd
LungFit (with ultra-high concentrations of nitric oxide)
clinical
Phase II trial enrolling July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Bronchiolitis and nontuberculous mycobacteria
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04397692, NCT04456088, NCT04606407
CytoSorbents Corporation
CytoSorb (blood purification device, extracorporeal cytokine adsorber))
clinical
Intervention trial started May 2020; Recruitment began Oct 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04324528, ChiCTR2000030475, NCT04344080, DRKS00021447, NCT04385771, NCT04344080, NCT04324528
ExThera Medical
Seraph100MicrobindAffinity Blood Filter (Seraphy 100), approved in the EU for pathogen reduction
clinical
DOD to fund a multi-center trial June 2020; FDA issued an Emergency Use Authorization on April 17, 2020
n/a
Funder
Funder
n/a
US Department of Defense (DOD)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04606498, NCT04470999, NCT04413955, NCT04361500, NCT04547257
Fresenius Medical
MultiFiltrate PRO System and multiBic/multiPlus Solutions, continuous renal replacement therapy (CRRT)
clinical
FDA issued an Emergency Use Authorization on April 30, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04871893
Terumo BCT Inc / Marker Therapeutics AG
Extracorporeal blood purification (EBP) devices, Spectra Optia® Apheresis System combined with D2000 Adsorption Cartridge
clinical
FDA issued an Emergency Use Authorization on April 9, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04358003
electroCore
gammaCore Sapphire CV, vagus nerve stimulation device
clinical
FDA granted Emergency Use Authorization July 10, 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Asthma
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04368156
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
AIM ImmunoTech/ National Institute of Infectious Diseases in Japan/ Roswell Park Comprehensive Cancer Center
Ampligen; (rintatolimod)
clinical
Phase I/II trial of Ampligen (rintatolimod), in combination with interferon alfa-2b, in cancer patients with COVID-19 not yet recruiting July 2020
n/a
Funder
Funder
n/a
National Cancer Institute
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04379518
Mateon Therapeutics
OT-101, a TGF-Beta antisense drug candidate
clinical
Phase II study IND submitted to FDA on April 27, 2020; Phase II trials approved in Peru Nov 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Neurimmune/ Ethris
Inhaled mRNA
pre-clinical
Phase I to start Q4 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sarepta Therapeutics / US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Antisense oligonucleotides, peptide conjugated
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sirnaomics
RNAi - testing 150 RNAis
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vir Biotech / Alnylam Pharmaceuticals
VIR-2703 (ALN-COV) siRNA candidate
pre-clinical
Phase I to start by the end of 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
Anixa Biosciences / OntoChem
Screening for antiviral drug candidates. Specified antiviral drug candidates: remdesivir
pre-clinical
Initial in silico screening completed July 2020, testing identified compounds in pre-clincial studies July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
COVID-19 Therapeutics Accelerator
Scanning compound libraries. Specifically small molecule drugs: monoclonal and polyclonal antibodies
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Gates Foundation / Wellcome / Mastercard Impact Fund
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Enanta Pharmaceuticals
Screening new drugs + library of antiviral compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Exscalate4Cov, public-private consortium
Screening a chemical library of 500 billion molecules
pre-clinical
Unknown
n/a
Funder
Funder
n/a
European Commision's Horizon 2020
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Healx
Artifical intellegence based screening to identify repurposed drug combinations. AI has specifically noted Baricitinib
pre-clinical
Combinations will be ready for pre-clinical testing in May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Janssen Pharmaceutical Companies
Scanning library of antiviral compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Materia Medica/Cyclica/Manin
Repurposing antiviral drug candidates
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Merck
CD24Fc (MK-7110) Scanning compounds to repurpose
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Novartis
Scanning compounds to repurpose
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Nuritas
AI-based screening to identify a peptide cocktail
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Partnership for Advanced Computing in Europe (PACE)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Pfizer
Scanning antiviral compounds previously in development
pre-clinical
Lead candidate (protease inhibitor) to start Phase I trial in Q3 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Quantitative Biosciences Institute Coronavirus Research Group
Reviewing existing drugs and compounds through mapping viral-human protein interactions
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Queens University Belfast
Scanning compounds to repurpose
pre-clinical
Unknown
n/a
Funder
Funder
n/a
UK Government
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sanford Burnham Prebys Medical Discovery Institute, the University of Hong Kong, Scripps Research, UC San Diego School of Medicine, the Icahn School of Medicine at Mount Sinai and UCLA
Identifying drugs to repurpose
pre-clinical
Identifying drugs to repurpose. Specified drugs: astemizole, clofazamine, remdesivir, chloroquine derivative hanfangchin A (tetrandrine), apilimod, and ONO 5334
n/a
Funder
Funder
n/a
US Department of Defense; California Institute for Regenerative Medicine
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Shionogi / Hokkaido University Research Center for Zoonosis Control
Identify novel drugs
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Southwest Research Institute
Screening drug compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Henry M. Jackson Foundation for the Advancement of Military Medicine
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Takeda
Scanning compounds to repurpose
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
N/A
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
The Castleman Disease Collaborative Network and the Center for Study & Treatment of Inflammatory Lymphadenopathies
Identifying drugs to repurpose
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vanda Pharmaceuticals / University of Illinois at Chicago
Screening of drug compounds
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vir Biotechnology / GSK
Identify anti-coronavirus compounds that target cellular host genes
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Wyss Institute
Identify FDA-approved drugs to repurpose to prevent or treat COVID-19
pre-clinical
Unknown
n/a
Funder
Funder
n/a
US Defense Advanced Research Projects Agency (DARPA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
I-SPY COVID Trial (Takeda)
Firazyr (icatibant), bradykinin B2 antagonist
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-002225-29, NCT04978051
4D Pharma
MRx-4DP0004, strain of Bifidobacterium breve isolated from the gut microbiome of a healthy human
clinical
Phase II enrolling July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Asthma
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04363372, EudraCT 2020-001597-30
ACCORD trial; University Hospital, Ghent/UCB Pharma 
Zilucoplan, a synthetic macrocyclic peptide inhibitor of the terminal complement protein C5
clinical
Phase II trial began recruitment July 2020 Patient enrollment began Dec 2020.
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Myasthenia gravis; immune-mediated necrotizing myopathy, ALS
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001736-95 (ACCORD Trial), NCT04382755
ACTIV-5/BET-B for COVID-19/National Institute of Allergy and Infectious Disease (NIAID)/Boehringer Ingelheim/AbbVie
risankizumab monoclonal antibody & remdesivir + lenzilumab
clinical
Phase 2 ACTIV-5 Big Effect Trial (BET-B) began Oct 2020
n/a
Funder
Funder
n/a
National Institute of Allergy and Infectious Disease (NIAID)/NIH
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04583969, NCT04583956
AI Therapeutics/ Yale University
LAM-002A (apilimod dimesylate), PIKfyve kinase inhibitor
clinical
Phase II trial started July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Lymphangioleiomyomatosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04446377
ARMS Pharmaceutical / UH Cleveland Medical Center / Case Western Reserve University
ARMS-1
clinical
Trial starts April 2020
n/a
Funder
Funder
n/a
Cleveland Foundation
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Influenza prophylaxis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
https://clinicaltrials.gov/ct2/show/NCT04644276?term=ARMS-1&cond=COVID&draw=2&rank=3
Aarhus University
senicapoc
clinical
Phase II trial ongoing July 2020; Phase II trials recruitment begin Oct 2020
n/a
Funder
Funder
n/a
The Danish Government
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Sickle cell anemia; Alzheimer's disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001420-34, NCT04594668
Abivax
ABX464
clinical
Phase IIb/III trial started July 2020, top line results expected in 2020
n/a
Funder
Funder
n/a
Bpifrance
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Ulcerative colitis; rheumatoid arthritis; hepatocellular carcinoma
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04393038, EudraCT 2020-001673-75
Aldeyra Therapeutics
ADX-629, orally available reactive aldehyde species (RASP) inhibitor
clinical
IND submission to FDA in June 2020; FDA approval to begin Phase II trials in Sept 2020; Phase II trials to begin 4th qtr 2020; Phase II began Dec 2020.
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Systemic immune-mediated diseases
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
https://www.clinicaltrialsarena.com/news/aldeyra-therapeutics-initiates-trials/
Aldeyra Therapeutics
ADX-1612, HSP 90 inhibitor
clinical
IND submission to FDA in June 2020; FDA approval to begin Phase II trials in Sept 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Algernon Pharmaceuticals
Cerocal (ifenprodil), NP-120, an NDMA receptor glutamate receptor antagonist targeting Glu2NB
clinical
Phase IIb/III trial to start July 2020. Patients enrolled Nov 2020. Patient enrollment complete Dec 2020.
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Idiopathic Pulmonary Fibrosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04382924
Amarin Corp
Vascepa (icosapent ethyl), a form of eicosapentaenoic acid
clinical
Unknown
n/a
Funder
Funder
n/a
Estudios Clínicos Latino América
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04412018, NCT04460651
Amgen; I-SPY COVID trial/Takeda/AbbieVie
Otezla (apremilast), inhibitor of phosphodiesterase 4 (PDE4)
clinical
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (I-SPY_COVID) starts July 2020. Enrolling patients August 2020. First patients enrolled Dec 2020.
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04488081
Apeptico/ Medical University Vienna
solnatide (synthetic molecule with a structure based on the lectin-like domain of human Tumour Necrosis Factor alpha)
clinical
Phase II trials ongoing July 2020; Individual expanded access in Austria April 2020
n/a
Funder
Funder
n/a
EU Commission (Horizon 2020 Program)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pneumonia, sepsis, ARDS, Primary Graft Dysfunction, and pulmonary dysfunctions
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001244-26
Applied Biology/ Brown University/ Corpometria Institute
dutasteride, anti-androgen
clinical
Unknown
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04446429, NCT04729491
Applied Therapeutics/ numerous New York City hospitals
AT-001, aldose reductase inhibitor
clinical
Phase II recruiting July 2020; Individual patient expanded access
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Diabetic cardiomyopathy
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04365699
Arch Biopartners
Metablok (LSALT peptide), selective dipeptidase-1 antagonist
clinical
FDA and Health Canada approved Phase II trial start in July 2020; Phase II trials approved to begin patient enrollment in Turkey Oct 2020; first patient dosed for Phase II trials in Turkey and US (Louisiana)
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Lung and Kidney Inflammation
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04402957
AstraZeneca/ Saint Luke's Mid America Heart Institute; Cambridge University Hospitals NHS Foundation Trust; TACTIC-E trial studying dapagliflozin + ambrisentan
Farxiga (dapagliflozin), sodium-glucose cotransporter 2 (SGLTs) inhibitor
clinical
Phase III study started in April 2020 (AstraZeneca)
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Heart failure; Chronic kidney disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04350593, NCT04393246
AstraZeneca; ACCORD study/Rigel Pharmaceuticals
Calquence (acalabrutinib), Bruton's tyrosine kinase (BTK) inhibitor
clinical
Case series results released June 2020; ACCORD Phase II trial to start May 2020; Phase 2 trial (fostamatinib) starts Sept 2020
n/a
Funder
Funder
n/a
UK Government (ACCORD study)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04346199, NCT04380688, EudraCT 2020-001736-95 (ACCORD Trial), EudraCT 2020-001644-25, NCT04497948
BerGenBio; ACCORD study
bemcentinib, selective AXL kinase inhibitor
clinical
ACCORD trial started June 2020, top line data expected summer 2020
n/a
Funder
Funder
n/a
UK Government (ACCORD study)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001736-95 (ACCORD Trial), NCT04890509
Beth Israel Deaconess, the University of Colorado Anschultz Medical Campus, and Denver Health (Genentech); University College London; Boehringer Ingelheim
Activase (alteplase), tissue plasminogen activator (tPA)
clinical
Phase II trial recruiting; Individual patient expanded access
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04357730, NCT04356833, EudraCT 2020-001640-26, NCT04453371, https://clinicaltrials.gov/ct2/show/NCT04640194?term=Activase&cond=COVID&draw=2&rank=4
BioAegis Therapeutics Inc.
recombinant human plasma gelsolin (rhu-pGSN)
clinical
Phase II trial has recruited one third of enrollees/Trial expanded to EU Dec 2020.
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Community-acquired pneumonia
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04358406
Biohaven/ Thomas Jefferson University
vazegepant, CGRP receptor antagonist
clinical
Phase II/III recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute migraine
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04346615
Biomarck Pharmaceuticals
BIO-11006, inhaled peptide
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute Respiratory Distress Syndrome; Non-Small Cell Lung Cancer; Chronic Obstructive Pulmonary Disease (COPD)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Blade Therapeutics
BLD-2660, synthetic small molecule inhibitor of calpain (CAPN) 1, 2, and 9
clinical
Enrollment completed for Phase II trials
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04334460
CTI Biopharma
pacritinib, oral kinase inhibitor with specificity for JAK2, IRAK1 and CSFIR
clinical
Phase III trial recruiting July 2020, results expected by the end of 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Myelofibrosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04404361
CalciMedica
Auxora (CM4620-IE), calcium release-activated calcium (CRAC) channel inhibitor
clinical
Open label phase II trial top line data released July 2020; Phase II trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pancreatitis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04345614
Can-Fite BioPharma
piclidenoson, A3 adenosine receptor agonist
clinical
IND (investigational new drug application) expected to be filed with FDA by end of July 2020; IND approved Sept 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Rheumatoid arthritis; psoriasis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04333472
Center for Clinical Metabolic Research, Gentofte Hospital
Entresto (sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker)
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001544-26, NCT04883528
Chimerix
DSTAT (dociparstat sodium), glycosaminoglycan derivative of heparin
clinical
Phase II/III trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute myeloid leukemia
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04389840
Constant Therapeutics LLC; Columbia University Irving Medical Center; ACTIV-4d RAAS; Vanderbilt University Medical Center; Multiple global research sponsors
TXA127 (human peptide angiotensin-(1-7))
clinical
Phase II trial initiated July 2020; Added to ACTIV-4d RAAS trial May 2021
n/a
Funder
Funder
n/a
NHLBI, FNIH, BARDA
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04401423, NCT04605887, NCT04924660
Cyclacel Pharmaceuticals / University of Edinburgh
fadraciclib (CYC065), cyclin-dependent kinase (CDK)2/9 inhibitor
clinical
Unknown
n/a
Funder
Funder
n/a
LifeArc
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Cyclacel Pharmaceuticals / University of Edinburgh
roscovitine seliciclib, cyclin-dependent kinase (CDK)2/9 inhibitor
clinical
Unknown
n/a
Funder
Funder
n/a
LifeArc
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Rheumatoid arthritis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Dompe farmaceutici (as part of Exscalate4CoV)
raloxifene (Evista), an estrogen agonist/antagonist
clinical
Safety/efficacy trials began in Italy Oct 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Eudra CT 2020-003936-25
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Eagle Pharmaceuticals / Amneal Pharmaceuticals / Alcami Corporation / Hackensack University Medical Center
Ryanodex (dantrolene sodium), skeletal muscle relaxant
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Eiger BioPharmaceuticals, Inc./ Johns Hopkins University
Peginterferon lambda
clinical
Phase II began in April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Hepatitis Delta
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04331899, NCT04344600
Eisai
Eritoran, TLR-4 antagonist
clinical
Added to REMAP-COVID trial in June 2020; First patient enrolled in Aug 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Sepsis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Evelo Biosciences/ Rutgers University/ Robert Wood Johnson University Hospital/ TACTIC-E trial (Cambridge University Hospitals NHS Foundation Trust)
EDP1815, oral single strain of microbe
clinical
Part of Phase II/III Phase TACTIC-E trial and interim data expected 4Q 2020; Phase II US trial to start August 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Psoriasis and Atopic Dermatitis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04393246
Exvastat Ltd / Global sponsors
Gleevec (imatinib), kinase inhibitor
clinical
Phase II and Phase III trials recruiting July 2020
n/a
Funder
Funder
n/a
Innovative Medicines Initiative
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04346147, NCT04357613, NCT04356495, NCT04422678, NCT04394416, EudraCT 2020-001435-27, EudraCT 2020-001321-31, NCT04794088, EudraCT 2020-005447-23, NCT04953052
Eyegate Pharma
PP-001
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Severe eye diseases
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
FSD Pharma
FSD-201 (ultramicronized palmitoylethanolamide)
clinical
Phase I topline results released June 2020; IND submitted to FDA Aug 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Respiratory infections
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Faron Pharmaceuticals / REMAP-CAP global trial/ WHO SOLIDARITY trial/ various global researchers
Traumakine (interferon beta 1-a)
clinical
Results from various trials released June 2020; REMAP-CAP trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT02735707, IRCT20100228003449N28, NCT04350671, NCT04343768, NCT04315948, NCT04492475
Feinstein Institutes for Medical Research at Northwell Health/ Alchem
Pepcid (famotidine), histamine-2 (H2) receptor antagonist
clinical
Phase II study underway in April 2020; Phase II trials recruiting Nov 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04389567, NCT04370262, NCT04565392, NCT04621149
Fulcrum Therapeutics
losmapimod, oral selective p38 mitogen activated protein kinase inhibitor
clinical
Phase III trial to begin June 2020; Enrollment began for Phase III trials, Phase III trial discontinued March 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Multiple indications, including facioscapulohumeral muscular dystrophy
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Genentech
MSTT1041A (anti-ST2, the receptor for IL-33)
clinical
Unknown
n/a
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04386616
Genentech
UTTR1147A (IL-22-Fc)
clinical
Unknown
n/a
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04386616
Genetic Engineering and Biotechnology Center (CIGB), Cuba
CIGB-258, immunoregulatory peptide, Jusvinza
clinical
Unknown
n/a
Funder
Funder
n/a
Ministry of Public Health of Cuba
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
https://rpcec.sld.cu/ensayos/RPCEC00000313-Sp,
Global research sponsors
TD139, specific inhibitor of galectin-3, inhalation powder
clinical
Unknown
n/a
Funder
Funder
n/a
Life Arc (University of Edinburgh)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001736-95 (ACCORD Trial), NCT04473053, ISRCTN14212905, EudraCT 2020-002230-32
Hebrew University of Jerusalem/ University of Pennsylvania/ University Arizona
Tricor (fenofibrate), peroxisome proliferator-activated receptor (PPAR) alpha agonist
clinical
Invite only intervention trial Sept 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04517396, NCT04661930
Heron Therapeutics
Cinvanti (aprepitant), a substance P/neurokinin-1 receptor antagonist
clinical
Phase II trial recruiting July 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04470622
I-SPY COVID Trial (Aerpio Pharmaceuticals), - RESCUE Trial various academic researchers/Medical Technology Enterprise Consortium (MTEC)
Razuprotafib, Tie 2 activating compound (AKB-9778)
clinical
Second trial to start in August 2020; Dosing began Phase II platform/I-SPY trial Sept 2020; Phase II/RESCUE Trial Sept 2020; Phase II Discontinued March 2021; Trials terminated June 2021
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04511650
I-SPY COVID Trial (Allergan); National Center for Advancing Translational Science (NCATS) Biomedical Advanced Research and Development Authority (BARDA)
Cenicriviroc, chemokine receptor 2 and 5 dual antagonist
clinical
Clinical trials to start in Aug 2020; ACTIV-1 1M Phase III trials began Oct 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Non-Alcoholic SteatoHepatitis (NASH)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04593940, EudraCT 2020-001493-29
Immunic, Inc./University Hospitals Coventry and Warwickshire NHS Trust
IMU-838, selective oral dihydroorotate dehydrogenase (DHODH) inhibitor
clinical
Phase II trial started June 2020, top line results expected in 2020, Recruiting Aug 2020 (IMU 838 +Oseltamivir); ; Phase II enrollment began Oct 2020
n/a
Funder
Funder
n/a
University Hospitals Coventry and Warwickshire NHS Trust
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Ulcerative colitis; remitting multiple sclerosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04516915, EudraCT 2020-001805-21, NCT04379271, EudraCT 2020-001264-28
ImmunityBio/ NantKwest
N-803, IL-15 "superagonist" (Nogapendekin alfa inbakicept)
clinical
Phase Ib trial to start June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Bladder Carcinoma In Situ
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04385849
Innovation Pharmaceuticals
Brilacidin, a defensin mimetic
clinical
Phase II trial anticipated to start Q4 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Oral Mucositis; Ulcerative Proctitis/Ulcerative Proctosigmoiditis; Acute Bacterial Skin and Skin Structure Infection
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Inotrem
Nangibotide
clinical
Phase II trial cleared by FDA, French and Belgian authorities July 2020; First patient dosed Oct 2020 (COVITREM- 1)
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Septic shock
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04429334, EudraCT 2020-001504-42
Insmed Inc.
brensocatib, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1)
clinical
Phase III trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Bronchiectasis and other inflammatory diseases
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001643-13, ISRCTN30564012
Institut National de la Sante et de la Recherche Medicale (Merck KGaA); IRCCS San Raffaele; WHO global SOLIDARITY Trial
Rebif (interferon beta-1a)
clinical
Phase III trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-000936-23, NCT04315948, 2020-001366-11 (Solidarity Spain), NCT04350671, NCT04449380, 2020-002060-31 (Solidarity Chech Republic), EudraCT 2015-002340-14 (REMAP-CAP), NCT04460547, EudraCT 2020-001549-38 (Solidarity Germany), NCT04647669
KD Pharma / SLA Pharma
EPAspire, oral formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Familial adenomatous polyposis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Karyopharm Therapeutics
Xpovio (selinexor), oral, selective inhibitor of nuclear export (SINE) compound
clinical
Phase II trial ongoing July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treat various cancers
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04355676, NCT04349098, EudraCT 2020-001411-25, NCT04534725
King's College London
Flarin (lipid ibuprofen)
clinical
Phase IV trial recruiting in July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04334629, EudraCT 2020-001203-16
Kintor/ Applied Biology
proxalutamide (GT0918), anti-androgen
clinical
1st patient enrolled in Brazil Aug 2020; Expanding patient enrollment Oct 2020, Female patient trial enrollment Dec 2020; Approval of investigational new drug application of phase III trial.
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04446429, NCT04728802, NCT04853134, NCT04870606, NCT04869228
Laurent Pharmaceuticals
LAU-7b (fenretinide)
clinical
Phase II trial recruiting July 2020, FDA approval to start enrollment August 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treat exaggerated inflammatory response in adult cystic fibrosis patients
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04417257
Massachusetts General Hospital; University of British Columbia; Sanotize Research and Development
Nitric oxide
clinical
Massachusetts General Hospital Phase II trial ongoing July 2020; other Phase II trials recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04305457, NCT04312243, NCT04306393, NCT03331445, NCT04443868, NCT04337918, NCT04456088, NCT04421508, NCT04383002, NCT04388683, NCT04338828, EudraCT 2020-001490-68, EudraCT 2020-001329-30, NCT04460183, NCT04443868, NCT04306393, NCT04476992
MediciNova/ Yale
MN-166 (ibudilast), orally bioavailable, small molecule macrophase migration inhibitory factor (MIF) inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor
clinical
Phase II trial FDA approved and not yet recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treatment of numerous neurodegenerative diseases and substance dependence
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04429555
MedinCell/ University of Utah/ Surgisphere Corp; University of Baghdad; Tanta University; other global research sponsors
ivermectin
clinical
Phase II to start in August 2020; Phase II began Oct 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04343092, NCT04345419, NCT04351347, NCT04407507, NCT04392713, NCT04425707, NCT04438850, NCT04405843, NCT04429711, NCT04374279, NCT04360356, NCT04381884, NCT04447235, NCT04435587, NCT04434144, NCT04445311, EudraCT 2020-001474-29, EudraCT 2020-002091-12, EudraCT 2020-001994-66, NCT04460547, NCT04431466, NCT04446104, NCT04446429, NCT04472585, ISRCTN40302986, EudraCT 2020-001971-33, NCT04482686, NCT04551755, NCT04602507, NCT04668469, NCT04673214, NCT04681053, NCT04701710
Merck KGaA
M5049, small molecule that block the activation of Toll-like receptor (TLR)7 and TLR8
clinical
FDA cleared Phase 2 trial to begin in June 2020; Phase 2 recruitment began Aug 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various immuology indications
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04448756
Multiple global research sponsors
Cozaar (losartan), angiotensin II receptor blocker (ARB)
clinical
Gates Foundation trial results expected by end of summer 2020; Phase III trials began Oct 2020 in Canada
n/a
Funder
Funder
n/a
COVID-19 Treatment Accelerator
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04312009, NCT04311177, NCT04349410, NCT04335123, NCT04343001, NCT04328012, NCT04340557, NCT04447235, NCT04428268, EudraCT 2020-001766-11, NCT04394117, NCT04467931, ISRCTN48734830, EudraCT 2020-002040-22, NCT04606563, https://clinicaltrials.gov/ct2/show/NCT04643691?term=Cozaar&cond=COVID&draw=2&rank=3
Multiple global research sponsors
Diovan (valsartan), angiotensin II receptor blocker (ARB)
clinical
Veterans observational study ongoing July 2020; Phase IV trials recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04335786, NCT04330300, NCT04394117, NCT04467931, EudraCT 2020-001544-26, EudraCT 2020-001431-27
Multiple global research sponsors, including UK SPIKE-1 trial
camostat mesylate, transmembrane protease serine 2 (TMPRSS2) inhibitor, approved in Japan to treat multiple conditions including pancreatitis
clinical
Phase I/II, Phase II, and Phase III trials recruiting in May 2020; Phase II (CAMELOT Trial) enrollment began Nov 2020
n/a
Funder
Funder
n/a
LIfeArc (SPIKE-1 trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04321096, NCT04353284, NCT04338906, NCT04374019, NCT04355052, EudraCT 2020-002233-15, NCT04455815, NCT04583592, NCT04652765, NCT04657497, NCT04662073, NCT04662086, NCT04782505
Multiple global research sponsors, including University of Tokyo/ National Center for Global Health and Medicine/ Ensysce Biosciences/ Institut Pasteur Korea/ Daiichi Sankyo (inhalation formulation)/ University of Edinburgh
nafamostat, approved in Japan to treat pancreatitis and other diseases
clinical
University of Tokyo trial (IV formulation) starts April 2020; Ensysce trial will be with oral formulation
n/a
Funder
Funder
n/a
Life Arc (University of Edinburgh)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04352400, NCT04418128, EudraCT 2020-002230-32, NCT04473053, ISRCTN14212905, https://clinicaltrials.gov/ct2/show/NCT04628143?term=nafamostat&cond=COVID&draw=2&rank=4, https://clinicaltrials.gov/ct2/show/NCT04623021?term=nafamostat&cond=COVID&draw=2&rank=5
Multiple global research sponsors; ACCORD Trial
heparin; low molecular weight heparin (enoxaparin), anticoagulant
clinical
Phase II/III/IV trials began June 2020; Sept 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04366960, NCT04360824, NCT04359277, NCT04354155, NCT04367831, NCT04345848, NCT04373707, NCT04372589, NCT04362085, NCT04344756, NCT04408235, NCT04406389, NCT04400799, NCT04377997, NCT04393805, NCT04427098, EudraCT 2020-001739-28, EudraCT 2020-001308-40, EudraCT 2020-001709-21, EudraCT 2020-001891-14, EudraCT 2020-001972-13, NCT04444700, NCT04466670, EudraCT 2020-001736-95 (ACCORD Trial), EudraCT 2020-001708-41, EudraCT 2020-001823-15, NCT04485429, NCT04461925, NCT04486508, NCT04511923, NCT04512079, NCT04530578, NCT04508439, NCT04528888, NCT04542408, NCT04545541, NCT04584580, NCT04635241, NCT04655586
NIH ACTIV-4 Antithrombotics/ nonprofit organizations/numerous biopharmaceutical companies
Apixaban (Eliquis) blood thinner, direct oral anticoagulant
clinical
Phase III trials for ACTIV-4 Antithrombotics launched Sept 2020; Recruitment began for Phase III trial Nov 2020
n/a
Funder
Funder
n/a
National Institute of Heart, Lung, and Blood Institute (NHLBI)/U.S. Operation Warp Speed
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04498273, NCT04650087, NCT04736901, NCT04746339, NCT04788355
National Institute of Allergy and Infectious Disease (NIAID)
Adaptive COVID-19 Treatment Trial 3 (ACTT-3), Remdesivir + interferon beta-1a
clinical
Phase III trial started August 2020
n/a
Funder
Funder
n/a
National Institute of Allergy and Infectious Diseases (NIAID)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04492475, NCT04315948, NCT04647669
National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial; Nova Scotia Health Authority; Hospital of Prato; University of Colorado (Eli Lilly); TACTIC-R trial
Olumiant (baricitinib), Janus kinase (JAK) inhibitor
clinical
Eli Lilly Phase III trial started June 2020; NIAID trial remdesivir + baricitinib recruiting May 2020, Received Emergency Use Authorization from the FDA in Nov 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04321993, NCT04320277, NCT04340232, NCT04280705, NCT04345289, NCT04346147, NCT04358614, NCT04373044, NCT04438629, NCT04421027, NCT04362943, NCT04393051, NCT04401579, NCT04390464, NCT04399798, NCT04365764, EudraCT 2020-001246-18, EudraCT 2020-001367-88, EudraCT 2020-001517-21, EudraCT 2020-001854-23, EudraCT 2020-001354-22 (TACTIC-R), EudraCT 2020-001321-31, EudraCT 2020-001052-18, ISRCTN11188345, NCT04640168, NCT04693026
NeoImmune Tech/ NIAID / University of Nebraska Medical Center
NT-I7 (efineptakin alfa), long-acting human IL-7
clinical
Phase I trial cleared by FDA July 2020; Second study for NT-I7 approved by FDA. Patient dosing began 2020.
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treat solid tumors
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04498325, NCT04501796, NCT04730427, NCT04810637
NeuroRx/ Relief Therapeutics/ Thomas Jefferson University Hospital/ NYU Langone Health/ Houston Methodist Hospital
Aviptadil, synthetic form of Vasoactive Intestinal Polypeptide (RLF-100)
clinical
Phase II/III trial ongoing July 2020; FDA grants Fast Track Designation June 2020; Expanded access protocols
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Sarcoid, Pulmonary Fibrosis, Bronchospasm, Erectile Dysfunction, and Acute Respiratory Distress Syndrome (ARDS)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04311697, NCT04453839, NCT04360096, NCT04536350, NCT04844580
Novartis / Incyte, numerous researchers globally
Jakafi/jakavi (ruxolitinib)
clinical
Novartis/Incyte Phase III trial started April 2020; Expanded access protocols
n/a
Funder
Funder
n/a
LIfeArc (RAVEN trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000029580, NCT04334044, NCT04331665, NCT04337359, NCT04348071, NCT04338958, NCT04348695, NCT04355793, NCT04354714, NCT04377620, NCT04362137, NCT04366232, NCT04361903, NCT04374149, NCT04338958, NCT04359290, NCT04414098, NCT04403243, EudraCT 2020-001754-21, EudraCT 2020-001963-10
Noveome Biotherapeutics/ Singota Solutions
ST266, cell-free biologic made from anti-inflammatory proteins secreted by placental cells
clinical
Phase I/II to start in Q4 2020; Phase I IV trials expected 1st QTR 2021
n/a
Funder
Funder
n/a
Commonwealth of Pennsylvania
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Multiple ophthalmic indications
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04720378
Noxopharm
Veyonda (idronoxil)
clinical
Phase I started July 2020; Phase I approved in Austrilia for NOXCOVID-1 trial to begin at clinical sites in Ukraine and Moldova
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Prostate cancer
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04488575
Numerous global sponsors
Recombinant human interferon alpha-1b
clinical
Phase III trial recruiting May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04320238, NCT04251871, NCT04275388
Numerous research sponsors globally
colchicine
clinical
Open-label Greek study results published June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04326790, NCT04328480, NCT04322565, NCT04322682, NCT04392141, NCT04375202, NCT04355143, NCT04360980, NCT04350320, NCT04416334, NCT04403243, NCT04363437, NCT04324463, NCT04367168, EudraCT 2020-001511-25, EudraCT 2020-001258-23, EudraCT 2020-001603-16, EudraCT 2020-001475-33, EudraCT 2020-001689-12, EudraCT 2020-001841-38, EudraCT 2020-001455-40, NCT04472611, NCT04516941, NCT04510038, NCT04527562, NCT04539873, NCT04654416, NCT04667780, NCT04867226
Numerous research sponsors globally
dipyridamole (Persantine), anticoagulant
clinical
Phase II recruiting July 2020; Individual patient expanded access
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04424901, NCT04391179, NCT04410328
Numerous trials with global research sponsors including World Health Organization SOLIDARITY trial; ORCHID trial with National Heart, Lung, and Blood Institute (NHLBI); REMAP-CAP global trial; Novartis; PRINCIPLE trial
Chloroquine/ Hydroxychloroquine, antimalarial
clinical
Brazilian study results released July 2020; Univ. of Minnesota early, mild outpatient trial results released July 2020; Prevention studies continue in Asia; NIH study stopped in June 2020; Novartis discontinues trial due to feasibility of recruitment in June 2020; WHO discontinues hydroxychloquine arm in the SOLIDARITY trial July 2020; FDA revoked the March 28, 2020 Emergency Use Authorization on June 15, 2020; RECOVERY trial prelim results released June 2020, trial arm stopped
n/a
Funder
Funder
n/a
COVID-19 Treatment Accelerator (University of Washington/ NYU trial and Mahidol Oxford Tropical Medicine Research Unit trial); UK Government (University of Oxford RECOVERY trial and PRINCIPLE trial); Life Arc (PIONEER trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Over 50 trials registered at Clinicaltrials.gov, including: NCT04261517, NCT04303507, NCT04303299, NCT04304053, NCT04307693, NCT04316377, NCT04315948, NCT04321993, ECT2020-001113-21, NCT04323527, NCT04333732, NCT04332991, NCT04345419, NCT04341870, NCT04345289, NCT02735707, NCT04351347, NCT04341493, NCT04332094, NCT04349410, NCT04286503, NCT04328012, NCT04346147, NCT04428268, NCT04350671, EudraCT 2020-001303-16, EudraCT 2020-001825-29, EudraCT 2020-00124618, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT 2020-001367-88, EudraCT number: 2020-00132131, EudraCT 2020-001357-52, NCT04434144, EudraCT 2020-001449-38, NCT04460547, NCT04446104, ISRCTN83971151 (Solidarity), EudraCT 2020-001366-11 (Solidarity Spain), EudraCT 2020-000982-18 (Norway Solidarity), NCT04381936 (RECOVERY), NCT04386070, NCT04330690, NCT04321616, EudraCT 2020-001448-24, EudraCT 2020-001723-13, EudraCT 2020-001528-32, NCT04435587, NCT04308668, NCT04376814, NCT04411433, NCT04392973, NCT04359615, NCT04387760, NCT04322123, EudraCT 2020-001605-23, NCT04365764, EudraCT 2020-001971-33
Numerous trials with research sponsors globally; University of Oxford RECOVERY trial; REMAP-CAP global trial; Covis Pharma B.V.
Methylprednisolone/ ciclesonide (Alvesco)/ hydrocortisone/ corticosteroids
clinical
Japan approves dexmethasone as COVID treatment July 2020; RECOVERY trial results released (dexamethasone) June/July 2020; Phase III trial to begin July 2020
n/a
Funder
Funder
n/a
UK Government (University of Oxford RECOVERY trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04244591, NCT04263402, NCT04273321, ChiCTR2000029656, ChiCTR2000029386, NCT02735707, NCT04330586, 2020-001113-21, NCT04345445, NCT04349410, NCT04329650, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT 2020-001854-23, EudraCT 2020-001413-20, NCT04381936 (RECOVERY), NCT04485429, NCT04461925, NCT04452565, NCT04484493
Ohio State University
VentaProst, inhaled epoprostenol delivered via a dedicated delivery system
clinical
Phase II trial currently recruiting patients
n/a
Funder
Funder
n/a
Aerogen Pharma Limited
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04452669
OncoImmune
CD24Fc, biological immunomodulator (nonpolymorphic regions of CD24 attached to the Fc region of human IgG1)
clinical
Phase III trial progress report released in June 2020
n/a
Funder
Funder
n/a
Merck
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Graft versus Host Disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04317040
Organicell Regenerative Medicine
Organicell Flow, acellular product derived from amniotic fluid
clinical
Phase I/II trial cleared by FDA in May 2020; Individual expanded access results released May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04384445, NCT04657406
Orpheris (Ashvattha Therapeutics)
OP-101, dendrimer-based therapy
clinical
FDA agreed to Phase II June 2020; patient enrollment began Sept 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04458298
PTC Therapeutics
PTC299, oral small molecule inhibitor of dihydroorotate dehydrogenase (DHODH)
clinical
Phase II/III trial initiated in Australia November 2020
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various oncology indications
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04439071, EudraCT 2020-001872-13
Partner Therapeutics/ Singapore General Hospital/ University Hospital, Ghent
Leukine (sargramostim, rhu-Granulocyte macrophage colony stimulating factor )
clinical
Phase II and Phase IV trials recruiting July 2020, enrollment for Phase II began August 2020
n/a
Funder
Funder
n/a
Other Transaction Agreement (OTA) with Department of Defense (DoD)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pulmonary conditions that affect alveolar macrophases (nebulized leukine); ARDS (IV leukine)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04326920, NCT04400929, NCT04411680, EudraCT 2020-001254-22, NCT04411680, https://clinicaltrials.gov/ct2/show/NCT04642950?term=Leukine&cond=COVID&draw=2&rank=4
Pfizer; other global research sponsors
Xeljanz (tofacitinib), Janus kinase (JAK) inhibitor
clinical
Pfizer and other Phase II trial not yet recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04332042, NCT04415151, NCT04390061, NCT04412252, NCT04469114, EudraCT 2020-001357-52, EudraCT 2020-002035-30
PharmaMar/ Boryung Pharmaceutical/ Hospitals in Spain
Aplidin (plitidepsin), approved in Australia to treat multiple myeloma
clinical
Phase I trial recruiting July 2020; Trials in Korea to start 3Q 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04382066, NCT04784559
Pharming
Ruconest (recombinant human C1 esterase inhibitor)
clinical
Phase II trial not yet recruiting July 2020; compassionate use; 2nd Phase II open label trial to start Sept 2020. First patient enrolled Dec 2020.
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04414631, NCT04530136
PhaseBio
PB1046, long-acting, sustained release human vasoactive intestinal peptide (VIP) analogue
clinical
Phase II trial started July 2020 and results in Q4 2020. Clinical trial terminated Dec 2020.
n/a
Funder
Funder
n/a
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pulmonary arterial hypertension
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04433546
Pulmotect
PUL-042 inhalation solution
clinical
Phase II trials recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Prevent and treat respiratory complications in immunosuppressed cancer patients
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04312997, NCT04313023
RECOVERY trial and multiple global research sponsors
azithromycin, antibiotic
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Over 100 clinical trials registered at clinicaltrials.gov; EudraCT 2020-001303-16, EudraCT 2020-001246-18, EudraCT 2015-002340-14 (REMAP-CAP), EudraCT 2020-001449-38, NCT04446429, EudraCT 2020-001723-13, EudraCT 2020-001113-21 (RECOVERY Trial), NCT04381936 (RECOVERY), NCT04411433, EudraCT 2020-001605-23, EudraCT 2020-001971-33, NCT04461925, NCT04321278, NCT04370782
REMAP-CAP trial
Levaquin (levofloxacin), a fluoroquinolone antibacterial
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2015-002340-14 (REMAP-CAP), NCT02735707 (REMAP-CAP)
REMAP-CAP trial
ceftriaxone, broad-spectrum cephalosporin antibiotic
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2015-002340-14 (REMAP-CAP), NCT02735707 (REMAP-CAP), NCT04869579
RedHill Biopharma
Yeliva (opaganib, ABC294640), oral sphingosine kinase-2 (SK2) selective inhibitor, orally administered
clinical
Phase II/III trials in Russia and UK to start in July 2020; Phase IIa in US ongoing in July 2020; Preliminary data from individual patient expanded access released in April 2020; Phase II/III approved for trials in Mexico, UK, Italy, and Russia; Global Phase II/III trial has passed 4 DSMB reviews
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various oncology indications
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04435106, NCT04414618, NCT04467840, EudraCT 2020-002677-95
RedHill Biopharma/ NIAID
RHB-107 (upamostat, WX-671), serine protease inhibitor, orally administered
clinical
Phase II/III trials begin 4th qtr 2020; Unique home-based phase II/III trial started March 2021.
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various oncology indications
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04723537
Resverlogix
apabetalone (RVX-208), selective BET (bromodomain and extra-terminal) inhibitor
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Treat various conditions
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04894266
Revive Therapeutics, Ltd.
Bucillamine, a cysteine derivative thiol-based drug
clinical
Phase III Trial began Nov 2020.
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04504734
Romark Laboratories; various researchers globally
nitazoxanide, antiprotozoal
clinical
Phase II/III and Phase III trials recruiting July 2020; Phase II trial completed (Brazil); Phase II trials began for the TriACT Trial Nov 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04351347, NCT04348409, NCT04343248, NCT04341493, NCT04345419, NCT04435314, NCT04441398, NCT04463264, NCT04459286, NCT04486313, NCT04423861, NCT04392427, NCT04406246, NCT04382846, NCT04552483, NCT04561219, NCT04605588
SciTech Development, LLC
ST-001 nanoFenretinide (fenretinide)
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
non-Hodgkin's lymphoma
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Senhwa Biosciences, Inc
Silmitasertib, small molecule drug, targets CK2 & CK2-inhibitor
clinical
FDA IIT approved was granted Aug 2020 for use in COVID patients, First patient dosed in Dec 2020.
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04663737, NCT04668209
Sun Pharmaceutical Industries Ltd
AQCH, plant-derived (phytopharmaeutical) drug
clinical
Phase II trial started June 2020, results expected by October
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Swedish Orphan Biovitrum/ REMAP-CAP global trial/ Numerous global trial sponsors
Kineret (anakinra), interleukin-1 receptor antagonist
clinical
Some trial results released June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04324021, NCT02735707, NCT04339712, NCT04330638, NCT04366232, NCT04443881, NCT04462757, EudraCT 2020-001636-95, EudraCT 2020-001825-29, EudraCT 2020-001734-36, EudraCT 2020-001466-11, EudraCT 2020-001754-21, EudraCT 2020-001963-10, EudraCT 2020-001739-28, EudraCT 2020-001500-41, EudraCT 2020-001246-18, EudraCT 2020-001039-29, EudraCT 2015-002340-14 (REMAP-CAP)
Synairgen/ University of Southampton
SNG001, inhaled formulation of interferon beta-1a
clinical
Phase II trial initial results released July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Asthma patients with cold or flu infection; COPD patients with viral infections
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04385095, NCT04732949
Trevena; REMAP-CAP COVID-19 ACE2 RAS Modulation Domain; ACTIV-4d RAAS; Vanderbilt University Medical Center; Imperial College London
TRV027 (Novel AT1 receptor-selective agonist)
clinical
Provisional patent application filed with US Patent and Trademark Office for ARDS and prevention/treatment of abnormal clotting in COVID-19 April 2020; Added to REMAP-CAP April 2021; Added to ACTIV-4d RAAS trial May 2021
n/a
Funder
Funder
n/a
NHLBI, FNIH, BARDA, Imperial College London
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04419610, NCT04924660
Union Therapeutics/ Institute Pasteur Korea/ Daewoong Therapeutics; First Wave Bio/ANA Therapeutics
UNI9011 (Union Therapeutics), FW-1022 (First Wave Bio), DWRX2003 (Daewoong) niclosamide
clinical
Danish Medicines Agency approved a Phase I trial July 2020 (UN9011, Union Therapeutics); Daewoong to apply for Phase I trial in Korea in July 2020; FDA cleared to begin clinical trials in Aug 2020; Dosing completed in Aug 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Atopic Dermatitis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04345419, NCT04399356, NCT04436458, EudraCT 2020-002233-15
University of Alabama at Birmingham; Leading Biosciences
Lysteda/Cyklokapron/LB1148 (tranexamic acid), an antifibrinolytic
clinical
Phase II recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04338074, NCT04338126, NCT04390217, NCT04550338
University of British Columbia/Apeiron Biologics
APN01; recombinant soluble human Angiotensin Converting Enzyme 2
clinical
Phase II trial recruiting July 2020. Patient enrollment complete Dec 2020.
n/a
Funder
Funder
n/a
Austrian Government
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Acute lung injury, Acute respiratory distress syndrome, Pulmonary arterial hypertension
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04335136, EudraCT 2020-001172-15
University of Hawaii (Boehringer Ingelheim); other global research sponsors
Micardis (telmisartan)
clinical
Phase II Univ. of Hawaii trial started June 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04360551, NCT04355936, NCT04359953, EudraCT 2020-001303-16, EudraCT 2020-001435-27, NCT04394117, NCT04466241, NCT04356495, NCT04467931, NCT04510662
Vanda Pharmaceuticals / Feinstein Institutes for Medical Research at Northwell Health
tradipitant, a neurokinin-1 receptor antagonist
clinical
Phase III trial started in April 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Gastroparesis, motion sickness, and atopic dermatitis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04326426
Various global research sponsors
Aldactone (spironolactone), aldosterone antagonist
clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001766-11, NCT04424134, NCT04345887, NCT04643691, NCT04826822
Various researchers globally, including University of Oxford
almitrine
clinical
Observational trial completed April in France;, Phase III trial recruiting Sept 2020 in France
n/a
Funder
Funder
n/a
LifeArc (University of Oxford trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Various lung diseases including Acute Respiratory Distress Syndrome (ARDS)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04357457, NCT04380727, EudraCT 2020-002567-57
Various researchers worldwide, including Ashford and St Peters Hospital NHS Trust/ Guangdong Uni-Innovation Pharmaceuticals Co., Ltd./ Clear Creek Bio, LLC/BMS
leflunomide, pyrimidine synthesis inhibitor; Dihydroorotate dehydrogenase inhibitor (DHODH- Brequinar)
clinical
FDA IND application accepted for Phase Ia/II open label safety trials began in summer 2020; First patient dosed for Phase I trial Sept 2020 (Brequinar); Phase II recruitment began Nov 2020 (CRISIS 2)
n/a
Funder
Funder
n/a
Life Arc (Ashford and St Peters Hospital NHS Trust/ Guangdong Uni-Innovation Pharmaceuticals Co., Ltd. trial)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04361214, NCT04575038, NCT04532372
Various researchers worldwide, including University College London/ The Francis Crick Institute (COVASE study)/ I-SPY COVID trial
Pulmozyme (nebulised dornase alfa), a recombinant DNase enzyme
clinical
Phase III trials recruiting June 2020
n/a
Funder
Funder
n/a
Life Arc (COVASE study)
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04409925, NCT04359654, NCT04387786, NCT04355364, NCT04402944, NCT04402970
Vicore Pharma
VP01, C21, Angiotensin II Type 2 receptor activator
clinical
Phase II dosing began of ATTRACT study in India
n/a
Funder
Funder
n/a
Life Arc
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pulmonary fibrosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04452435, NCT04878913, NCT04880642
ViralClear Pharmaceuticals
merimepodib, IMPDH inhibitor
clinical
Phase II trial recruiting July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Chronic Hepatitis C; Psoriasis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04410354 (terminated)
Washington University School of Medicine in St. Louis/ Covid-19 Early Treatment Fund (CETF)
Luvox (fluvoxamine), a selective serotonin reuptake inhibitor
clinical
Phase II trial recruiting May 2020; Phase II trial completed Oct 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04342663, NCT04668950, NCT04711863, NCT04718480, NCT04727424, NCT04885530
Zydus Cadila Group; The Camelot Foundation
interferon/peginterferon alpha-2b, PegIntron, Sylatron, IntronA, PegiHep
clinical
Phase II/III enrolling May 2020. Phase III began Dec 2020.
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04273763, NCT04349410, NCT04379518, NCT04647695
Zydus Cadila/ Avant Sante Research Center
desidustat, a hypoxia inducible factor prolyl hydroxylase inhibitor
clinical
Phase IIb trials approved to start in Mexico July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Chronic Kidney Disease
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04463602
aTyr
ATYR1923, fusion protein (immuno-modulatory domain of histidyl tRNA synthetase fused to the Fc region of a human antibody) modulator of neuropilin-2
clinical
Phase II study started in June 2020; Phase 2 enrollment completed Oct 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Pulmonary sarcoidosis
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04412668
BioIncept
sPIF (synthetic pre implantation factor)
pre-clinical
Preparing for a Phase I/IIa trial in May 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Bioxytran
BXT-25; glycoprotein
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CEL-SCI / University of Georgia Center for Vaccines and Immunology
LEAPS COVID 19 conjugate; Peptides targeting the NP protein
pre-clinical
Animal study results released July 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chelation Partners
DIBI, iron-binding polymer
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Lupa Bio, Inc.
New drug based on a sugar found in human milk
pre-clinical
Plans to sumit an IND in 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Merck/ IRBM/ RaPharma
PCSK9, Peptides
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Moleculin Biotech/ University of Texas Medical Branch/ Sterling Pharma USA
WP1122, glucose decoy prodrug (and related drug candidates)
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NanoViricides/ TheraCour Pharma Inc.
A number of synthesized nanoviricide drug candidates
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Nocion Therapeutics
Nocions, molecules that either selectively block Nav 1.7 or antagonize large-pore channels
pre-clinical
Phase I trial to start July 2020; First patient dosed Sept 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Persephone Biosciences
Microbiome therapeutic
pre-clinical
Clinical trials to start in 2020
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Pneumagen Ltd.
Neumifil, multivalent carbohydrate binding molecules
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Quotient Sciences/ CytoAgents
GP1681, small molecule inhibitor of cytokine release
pre-clinical
Phase I/II to start in 2020
n/a
Funder
Funder
n/a
Richard King Mellon Foundation
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Silkim Pharma
Coronzot, a novel family of drugs, sequestration of the labile iron
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
pHbarrier
pH barrier, transepithelial nebulized alkaline treatment
pre-clinical
Unknown
n/a
Funder
Funder
n/a
Unknown
Clinical Trials for Other Diseases
Clinical Trials for Other Diseases
n/a
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PHASE
Anticipated Next Steps
A successful vaccine would be able to protect the population from COVID-19. Developers from around the world are using different platforms, from tested ways to induce immunity in a vaccinated person (e.g., live attenuated virus vaccines), to innovative platforms never used before (e.g., DNA-based vaccines), to build vaccines to protect people against COVID-19 disease. Each type offers unique benefits and challenges and we will likely need more than one approved vaccine to vaccinate every person around the globe.
Zydus Cadila Healthcare Limited
DNA; (ZyCoV-D) plasmid vaccine
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
India granted "emergency use approval" for use in adults and children aged 12 years and above on 8/20/2021; Applied to the office of Drug Controller General of India (DCGI) for EUA on 7/1/2021; Phase III data expected to be announced May 2021; Phase III dosed January 2021; Pre-clinical results released January 2021; DCGI approved start of Phase III trial in January 2021; Phase I/II study: Phase I began July 2020 and Phase II began August 2020, initial results expected September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/07/026352, CTRI/2021/01/030416
Inovio Pharmaceuticals/ Beijing Advaccine Biotechnology/ VGXI Inc./ Richter-Helm BioLogics/ Ology Bioservices/ International Vaccine Institute/ Seoul National University Hospital/ Thermo Fisher Scientific/ Kaneka Eurogentec
DNA; (INO-4800) plasmid vaccine with electroporation
stage-2half3
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense
Related use
Related use
n/a
Same platform as multiple vaccine candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III efficacy trial receives authorization to proceed from Brazil's ANVISA on 8/26/2021; Phase II preliminary results released on 5/7/2021; ex-US Global Phase III trial planning announced 4/23/2021; Study results on the human immune responses against variants of concern announced 4/15/2021; Phase I data published December 2020; Phase II dosed December 2020, as part of its Phase II/III clinical trial (INNOVATE); FDA partial clinical hold for planned Phase II/III trial reported on 9/28/2020; Phase I/IIa trial began July 2020; Animal study results released July 2020; Joined US Operation Warp Speed in June 2020; Phase I began April 2020, interim data of ongoing study released June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000038152, ChiCTR2000040146, NCT04336410, NCT04447781, NCT04642638
Osaka University/ AnGes/ Takara Bio/ Cytiva/ Brickell Biotech
DNA; (AG0301 & AG0302) plasmid vaccine + adjuvant
stage-2half3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III trial began December 2020; Pre-clinical study results released October 2020; Phase I/II trials began end of June (AG0301) and August (AG0302) 2020, results expected during Q1 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
jRCT2051200085, jRCT2051200088, NCT04463472, NCT04527081, NCT04655625
Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and Technology (POSTECH)/ Binex/ PT Kalbe Pharma
DNA; (formerly GX-19) (GX-19N)
stage-1half2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III study expected to begin in Indonesia as of July 2021; Phase IIa began February 2021; Updated development plan to GX-19N formula and will reconduct Phase I/IIa study as of December 2020. Phase I of Phase I/IIa study began end of June 2020; Animal study results announced August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04445389, NCT04715997
GeneOne Life Science
DNA; (GLS-5310)
stage-1half2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase IIa expected to be dosed July 2021; Phase I/IIa began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04673149
Entos Pharmaceuticals/ Cytiva
DNA; (Covigenix)
stage-1half2
Funder
Funder
n/a
Canadian Institutes of Health Research (CIHR)/ Research Nova Scotia (RNS)/ Institute for Ageing (IA)/ National Research Council of Canada Industrial Research Assistance Program (NRC IRAP)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04591184
Takis/ Applied DNA Sciences/ Evvivax/ Rottapharm Biotech
DNA (COVID-eVax)
stage-1half2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began March 2021, announced the authorization of the clinical trial by the Italian Medicines Agency (AIFA) on 2/3/2021; Pre-clinical results released in May and July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-003734-20, NCT04788459
BioNet Asia/ Technovalia/ Vax4COVID/ The University of Sydney/ The University of Western Australia/ Telethon Kids Institute/ PharmaJet
DNA; (COVIGEN) needle-free delivery
stage-1
Funder
Funder
n/a
Australian Government Medical Research Future Fund (MRFF)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I dosed end of June 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04742842
Symvivo
DNA; bacTRL-Spike
stage-1
Funder
Funder
n/a
National Research Council of Canada Industrial Research Assistance Program (NRC IRAP)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I dosed November 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04334980
OncoSec Medical Incorporated / Providence Cancer Institute
(CORVax12), IL-12 expression platform + “S” glycoprotein
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I dosed January 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04627675
Scancell/ University of Nottingham/ Nottingham Trent University
DNA; plasmid vaccine RBD&N
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I COVIDITY clinical trial expected to start as soon as possible during 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Statens Serum Institute, Denmark
DNA; (CoVAXIX) plasmid vaccine
pre-clinical
Funder
Funder
n/a
Folketing's Finance Committee
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I is expected to start in late 2020 or early 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Institute of Chemistry, Slovenia
Plasmid DNA, nanostructured RBD
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Globe Biotech Limited, Bangladesh
DNA plasmid vaccine
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Cambridge/ DIOSynVax/ PharmaJet
DNA; (DIOS-CoVax2) synthetic gene inserts compatible with multiple delivery systems
pre-clinical
Funder
Funder
n/a
Innovate UK
Related use
Related use
n/a
Influenza, Ebola
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin late fall 2020 or early 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Mediphage Bioceuticals/ University of Waterloo/ Lambton College
DNA; msDNA-VLP
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Immunomic Therapeutics/ EpiVax/ PharmaJet
DNA; plasmid vaccine, needle-free delivery
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chula Vaccine Research Center
DNA with electroporation
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
OPENCORONA Project: Karolinska Institute/ Justus Liebig University Giessen/ Public Health Agency of Sweden (FoHM)/ IGEA/ Cobra Biologics/ Adlego Biomedical/ Region Stockholm
DNA with electroporation
pre-clinical
Funder
Funder
n/a
European Commission (Horizon 2020 Program)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin in 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Research Centre, Egypt
DNA; plasmid vaccine S, S1, S2, RBD & N
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Ege University Drug Development and Pharmacokinetic Research Application Center (ARGEFAR)/ Scientific and Technological Research Council of Turkey (TUBITAK)
DNA
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer/ Researcher
Product Description
Phase
PRE
I
II
III
RR
AU
Sinovac/ Instituto Butantan/ Bio Farma
Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc); VACSERA in Egypt
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
The Egyptian Drug Authority (EDA) granted the Sinovac/VACSERA vaccine an emergency use license on 8/23/2021; Phase I/II clinical trials results in healthy children and adolescents aged 3-17 in China published 6/28/2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 6/1/2021; Summary of clinical trial data released on 4/3/2021; Emergency use approval, or conditional marketing authorization, has been granted by over 30 countries as of 4/1/2021; Malaysia granted "conditional approval" on 3/2/2021; China's NMPA granted "conditional marketing authorization" on 2/8/2021; Phase III results (Brazil, Turkey, Indonesia, Chile) announced on 2/5/2021; Phase I/II safety, tolerability, and immunogenicity data in adults aged 60 years and older published on 2/3/2021; Sinovac filed for "conditional market authorization" with China’s National Medical Products Administration (NMPA) on 2/3/2021; Chile granted "emergency use" approval on 1/20/2021; Brazil granted "temporary authorization for emergency use" on 1/17/2021; Turkey granted "emergency use authorization" on 1/31/2021; Indonesia granted "emergency use approval" on 01/11/2021; Phase III efficacy results (Brazil) released early January 2021; Phase I/II complete analysis results published 11/17/2020; Phase III trial resumed in Brazil on 11/11/2020, Phase III trial suspended in Brazil on 11/09/2020; Received approval for Phase I/II trial in adolescents and children in September 2020; Phase III trial began end of July 2020; Phase II began June 2020, mid-phase II results released August 2020; Preliminary results from Phase I/II trials released June and September 2020 (aged 60+) 2020; Received early approval for "emergency use" in China (Aug 2020)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04383574, NCT04352608, NCT04456595, NCT04551547, NCT04508075, NCT04582344, NCT04617483, NCT04651790, 669/UN6.KEP/EC/2020
Valneva/ Dynavax/ National Institute for Health Research, United Kingdom
Inactivated (Inactivated + CpG 1018), VLA2001
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Japanese Encephalitis
Anticipated Next Steps
Anticipated Next Steps
n/a
Initiated a further Phase III trial with participants aged 56 years and older in August 2021; Phase III began April 2021; Phase I/II data announced April 2021; Phase I/II began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04671017, NCT04864561
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology/ Ocugen/ Precisa Medicamentos
Inactivated; whole-virion (COVAXIN) (BBV152)
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III efficacy analysis results announced on 7/2/2021; Phase III second interim analysis results announced on 4/21/2021; Authorized for "emergency use" in Nepal and Zimbabwe as of March 2021; Phase II interim analysis and Phase I follow-up results published 3/8/2021; Phase III interim analysis results announced 3/3/2021; Neutralization of UK-variant with vaccine-elicited sera announced January 2021; India granted "permission for emergency use" on 01/03/2021; Phase I and II safety and immunogenicity data released December 2020 and published January 2021; Phase III began November 2020; Phase I/II study: Phase I began July 2020 and Phase II began September 2020, initial results expected September 2020; Animal study results released September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/07/026300, NCT04471519, CTRI/2020/09/027674, CTRI/2020/11/028976, NCT04641481
Erciyes University
Inactivated; (ERUCOV-VAC), (TURKOVAC)
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III began June 2021; Phase II dosed February 2021; Phase I began November 2020, completed on December 14, 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04691947, NCT04824391, NCT04942405
Shenzhen Kangtai Biological Products Co.,Ltd./ Beijing Minhai Biotechnology Co., Ltd.
Inactivated SARS-CoV-2 vaccine, Vero cell, (KCONVAC)
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III began June 2021; Received early approval for "emergency use" in China in May 2021; Phase I/II results announced April 2021; Phase I/II study began October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000038804, ChiCTR2000039462, NCT04758273, NCT04756323, NCT04852705
Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of the Russian Academy of Sciences
Whole virion inactivated vaccine, CoviVac
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III began March 2021; Russia "registered" the vaccine in February 2021; Clinical trials began Ocotober 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Beijing Institute of Biological Products/ Sinopharm
Inactivated, (BBIBP-CorV)
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Vietnam granted approval on 6/4/2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 5/7/2021; Indonesia granted "emergency use" approval on 4/30/2021; Hungary granted "emergency use" approval on 1/29/2021; Pakistan granted "emergency use authorization" on 1/18/2021; China "granted conditional market approval" on 12/31/2020; Midterm clinical results released on 12/30/2020; Bahrain National Health Regulatory Authority (NHRA) "approved" on 12/13/2020; UAE Ministry of Health and Prevention (MOHAP) announced "official registration" on 12/9/2020, following review of Phase III interim analysis; Phase I/II results published October 2020; Phase III trial began July 2020; Received early approval for "emergency use" in China (Aug 2020) and the UAE (Sep 2020)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000032459, ChiCTR2000034780, NCT04510207, NCT04560881
Research Institute for Biological Safety Problems, Republic of Kazakhstan
Inactivated, (QazCovid-in®)
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Kazakhstan lauched nationwide vaccine roll out as of 4/27/2021; Kazakhstan granted "temporary registration for nine months" as of 1/13/2021; Phase III began December 2020; Phase I/II began September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04530357, NCT04691908
Wuhan Institute of Biological Products/ Sinopharm
Inactivated
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
China granted "conditional approval" on 2/25/2021; Applied for regulatory approval in China as of February 2021; Phase III trial began July 2020; Phase I/II early trial results released June 2020, Phase I/II interim analysis published August 2020; Received early approval for "emergency use" in China (Aug 2020) and the UAE (Sep 2020)
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000031809, ChiCTR2000034780, ChiCTR2000039000, NCT04510207, NCT04612972
Institute of Medical Biology, Chinese Academy of Medical Sciences
Inactivated
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III dosed (Malaysia) late January 2021; Phase II began June 2020; Phase I began May 2020, results released October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04412538, NCT04470609, NCT04659239
Shifa Pharmed Industrial Co
COVID-19 inactivated vaccine (COVIran Barekat)
stage-2half3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Iran granted emergency use authorization on 6/14/2021; Phase II/III trial in adults 18-75 years of age began March 2021; Phase I trial in adults 51-75 years of age began March 2021; Phase I trial in adults 18-50 years of age began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IRCT20201202049567N1, IRCT20201202049567N2, IRCT20201202049567N3
Government Pharmaceutical Organization (GPO; Thailand) / Dynavax / PATH
Inactivated, Newcastle Disease Virus (NDV) based chimeric vaccine with or without the adjuvant CpG 1018; (NDV-HXP-S)
stage-1half2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04764422
KM Biologics
Inactivated (inactivated + alum); (KD-414)
stage-1half2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for JE, Zika
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II study began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
jRCT2071200106
Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax / PATH
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018, (COVIVAC)
stage-1half2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II began March 2021, Phase I is expected to be completed by end of May 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04830800
Laboratorio Avi-Mex/ National Council of Science and Technology, Mexico/ Agencia Mexicana de Cooperación Internacional para el Desarrollo (AMEXID)
Recombinant Newcastle disease virus (rNDV), ("Patria")
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began May 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04871737
Scientific and Technological Research Council of Turkey (TUBITAK)
Adjuvanted inactivated vaccine
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began end of April 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04866069
Kocak Farma Ilac ve Kimya San. A.S.
Inactivated
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04838080
National Research Centre, Egypt
Inactivated; whole virus; (NRC-VACC-01)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical study results published March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Institute Butantan (Brazil) / Dynavax / PATH
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sinovac/ Dynavax
Inactivated + adjuvant (CpG 1018)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Selcuk University
Inactivated
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Osaka University / BIKEN / NIBIOHN
Inactivated
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer/ Researcher
Product Description
Phase
PRE
I
II
III
RR
AU
Meissa Vaccines 
Intranasal live-attenuated chimeric vaccine candidate, (MV-014-212)
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for RSV
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical data released August 2021; Phase I enrollment began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04798001
Codagenix / Serum Institute of India
Single-dose, intranasal, live attenuated vaccine, (COVI-VAC)
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical research published June 2021; Phase I trial dosed January 2021, initial data expected by mid-2021; Phase I recruitment began December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04619628
Indian Immunologicals Ltd/ Griffith University
Codon deoptimized live attenuated virus
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Mehmet Ali Aydinlar University/ Acıbadem Labmed Health Services A.S.
Codon deoptimized live attenuated vaccines
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer/ Researcher
Product Description
Phase
PRE
I
II
III
RR
AU
Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent BioSolutions/ Catalent/ Biological E/ Grand River Aseptic Manufacturing (GRAM)/ Sanofi/ Merck
Ad26.COV2-S (or JNJ-78436725), Non replicating viral vector; Ad26 (alone or with MVA boost)
stage-authorized
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola, HIV, RSV
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/IIa sub-study results published 7/14/2021; Johnson & Johnson statement on COVID-19 vaccine released 7/12/2021; Data on neutralizing activity against emerging variants announced 7/1/2021; U.K. MHRA granted "conditional marketing authorization" on 5/28/2021; CDC and FDA lift recommended pause on vaccine use in U.S. on 4/23/2021; Phase III ENSEMBLE primary data published on 4/21/2021; CDC and FDA recommended a pause on vaccine use in the U.S. as of 4/13/2021; Phase IIa trial expanded to include adolescents 12-17 years of age as of 4/2/2021; WHO issued "emergency use listing" on 3/12/2021; Granted Conditional Marketing Authorization by European Commission on 3/11/2021; Granted "Interim Order (IO) authorization" for emergency use by Health Canada on 3/5/2021; U.S. CDC's Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine for individuals 18 years of age and older on 2/28/2021; U.S. FDA issued "emergency use authorization" on 2/27/2021; Submitted "emergency use listing" to the World Health Organization (WHO) on 2/19/2021; Submitted "conditional marketing authorisation application" to the European Medicines Agency (EMA) on 2/16/2021; Janssen submitted application for "emergency use authorization" to the U.S. FDA on 2/4/2021; Phase III interim analysis results announced 1/29/2021; Phase I/IIa interim results published 1/13/2021; Phase III trial to study the safety and efficacy of a two-dose regimen began 11/15/2020 (ENSEMBLE 2); Phase III trial (ENSEMBLE) resumed recruitment on 10/23/2020, fully enrolled with ~45,000 participants as of 12/17/2020, interim data expected by the end of January 2021; Janssen Pharmaceutical Companies of Johnson & Johnson voluntarily paused dosing to allow independent review of safety data on 10/12/2020; Phase III trial (ENSEMBLE) began and study protocol released September 2020; Phase I/IIa began end of July 2020, interim results released September 2020; Animal study results published July and September 2020; Selected for US Operation Warp Speed in February 2020 and awarded funding in August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-002584-63, ISRCTN14722499, NCT04436276, NCT04505722, NCT04509947, NCT04535453, NCT04614948, NCT04765384
University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA
Non replicating viral vector; COVID-19 Vaccine AstraZeneca in the U.K. (formerly AZD1222 and ChAdOx1), Covishield in India, (Vaxzevria)
stage-authorized
Funder
Funder
n/a
Coalition for Epidemic Preparedness Innovations (CEPI)/ UK Government/ Biomedical Advanced Research and Development Authority (BARDA)/ Gavi, the Vaccine Alliance
Related use
Related use
n/a
Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague
Anticipated Next Steps
Anticipated Next Steps
n/a
Tolerability and immunogenicity results after a late second dose or a third dose released on 6/28/2021; Real-world data on vaccine effectiveness against hospitalizations due to the Delta variant released 6/14/2021; Japan granted authorization for "emergency use" on 5/21/2021; EMA updated guidance on very rare side effects announced 4/7/2021; Phase II dosing paused in children between the ages of 6 and 17 years pending MHRA review as of 4/6/2021; Phase III primary analysis (U.S. trial) results announced 3/25/2021; Phase III interim analysis (U.S. trial) results announced 3/22/2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 2/15/2021; Phase II study in children between the ages of 6 and 17 years expected to begin in February 2021; Phase III (U.K., Brazil) and Phase I/II (U.K., South Africa) analyses data released on 2/3/2021; European Union (EU) granted "conditional marketing authorisation" on 1/29/2021; Brazil granted "temporary authorization for emergency use" on 1/17/2021; Pakistan granted "emergency use authorization" on 1/15/2021; India granted "emergency use authorisation" as well as Dominican Republic, El Salvador, Mexico and Morocco as of 1/6/2021; Argentina authorized under "emergency registration" on 12/30/2020; U.K. "authorised for emergency supply" on 12/30/2020; Phase I/II data (w/ booster dose) published on 12/17/2020; Phase III trials interim analysis results published 12/8/2020; Phase II/III (COV002) and Phase III (COV003) trial pooled interim analysis results released on 11/23/2020; Phase II/III trial interim results released Nov 2020; Study protocol for late-stage clinical trials released September 2020; AstraZeneca clinical trials resumed globally (in the UK on 9/14/2020, Brazil and South Africa on 9/15/2020, Japan on 10/2/2020, and the US on 10/23/2020); AstraZeneca voluntarily paused vaccination to allow independent review of safety data on 9/8/2020; Phase III trial began Jun 2020 and expanded into US in Aug 2020; Phase II/III began May 2020; Phase I/II trial interim results released Jul 2020; Selected for US Operation Warp Speed in May 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/08/027170, EudraCT 2020-001072-15, EudraCT 2020-001228-32, ISRCTN15638344, ISRCTN89951424, NCT04324606, NCT04400838, NCT04444674, NCT04516746, NCT04540393, NCT04568031, NCT04686773, PACTR202005681895696, PACTR202006922165132
Gamaleya Research Institute
Adeno-based; (Gam-COVID-Vac) (Sputnik V)
stage-3
Funder
Funder
n/a
Russian Direct Investment Fund (RDIF)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Final results of trials are expected to be ready by October 2021; Demonstrated efficacy based on the analysis of data from vaccinated persons announced on 4/19/2021; Started rolling review process with the European Medicines Agency (EMA) on 3/4/2021; Authorized for "emergency use" in 39 countries as of March 2021; Phase III interim analysis results published on 2/2/2021; "Registered" in Belarus in December 2020; Phase III final control point data analysis results released December 2020, interim data analysis results released November 2020; Phase III (post-registration) trial began September 2020; Phase I/2 began June 2020, results published September 2020; Russian Ministry of Health "registered" vaccine in August 2020, Mass production expected to begin September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04436471, NCT04437875, NCT04530396, NCT04564716, NCT04587219, NCT04640233, NCT04642339, NCT04656613, NCT04713488, NCT04741061
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax
Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV), (Convidecia™)
stage-3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for EBOV
Anticipated Next Steps
Anticipated Next Steps
n/a
Authorized for "emergency use" in Argentina, Chile, Hungary, Pakistan, and Mexico, and for "conditional approval" in China as of June 2021; Filed "conditional marketing authorization" with China's National Medical Products Administration (NMPA) on 2/24/2021; Phase III dosed September 2020; Phase II began April 2020, initial results released May 2020, mid-phase results released July 2020; China’s Central Military Commission "approved the use of the vaccine by the military" in June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000030906, ChiCTR2000031781, NCT04313127, NCT04341389, NCT04398147, NCT04526990, NCT04540419, NCT04552366, NCT04566770, NCT04568811
AstraZeneca
Non-replicating viral vector; (AZD2816)
stage-2half3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II/III dosed end of June 2021, in both previously vaccinated (with two doses of Vaxzevria or an mRNA vaccine) and unvaccinated adults to determine the safety and immunogenicity of AZD2816, a vaccine for the prevention of COVID-19 caused by variant strains of the SARS-CoV-2 virus
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04973449
ReiThera/ Leukocare/ Univercells/ National Institute of Infectious diseases Lazzaro Spallanzani
Non-replicating viral vector; replication defective simian adenovirus encoding SARS-CoV-2 S (GRAd-CoV2)
stage-2half3
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II preliminary data announced July 2021; Phase II/III (COVITAR) study began March 2021; Phase I advanced to second set of three cohorts (aged 65-85 years) in November 2020; Phase I began August 2020, completed the first set of three cohorts (aged 18-55 years), preliminary results announced November 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-002835-31, EudraCT 2020-005915-39, NCT04528641, NCT04791423
ImmunityBio/ NantKwest
Non-replicating viral vector; [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid; (subcutaneous, oral, and sublingual delivery)
stage-1half2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for flu, Chik, Zika, EBOV, LASV, HIV/SIV, cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II/III trial expected to begin Q3 2021 and will study the efficacy, safety, and immunogenicity of ImmunityBio’s T-Cell COVID-19 vaccine as a boost in participants who have already received a spike-only antibody-based vaccine; Expanded trials to test vaccine candidate as a ‘universal boost’ in vaccinated subjects and received approval to test intranasal spray in South Africa as of May 2021; Phase I/II supplemental vaccine boost trial began April 2021; Phase Ib preliminary findings reported on 4/8/2021; Phase I interim safety data announced on 3/15/2021; Phase I dosed in South Africa and the U.S. in March 2021; FDA authorized the expansion of the active Phase I trial and a second trial to test a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a room-temperature oral or sublingual boost; Phase I interim data announced November 2020; Pre-clinical data released December, November, and July 2020; Phase I trial dosed in the U.S. in October 2020; Selected for US Operation Warp Speed in May 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04591717, NCT04710303, NCT04732468, NCT04843722, NCT04845191
Shenzhen Geno-Immune Medical Institute
LV-SMENP-DC vaccine and antigen-specific CTLs
stage-1half2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II reportedly began March 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04276896
CyanVac LLC
Intranasal PIV5-vectored vaccine expressing SARS-CoV-2 spike protein; (CVXGA1-001)
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began August 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04973449
City of Hope Medical Center
MVA-based SARS-CoV-2 vaccine; (COH04S1)
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II expected to begin August 2021; Phase I dosed December 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04639466, NCT04977024
German Center for Infection Research (DZIF)/ IDT Biologika GmbH/ Universitätsklinikum Hamburg-Eppendorf/ Philipps University Marburg Medical Center/ Ludwig-Maximilians University of Munich
Non-replicating viral vector; MVA-S encoded
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for many pathogens
Anticipated Next Steps
Anticipated Next Steps
n/a
Spike protein of the vector vaccine has now been modified and clinical testing will resume as of 7/16/2021; Phase I/II expected to begin July 2021; Clinical testing suspended January 2021, Phase II postponed until further notice; Phase I dosed October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04569383, NCT04895449
Gritstone Oncology, Inc.
Chimpanzee Adenovirus serotype 68 (chAd) and Self-Amplifying mRNA (SAM) vectors expressing either spike alone, or spike plus additional SARS-CoV-2 T cell epitopes (TCE)
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I dosed March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04776317
Vaxart/ Emergent BioSolutions
Non-replicating viral vector; Oral Vaccine platform
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II expected to begin Q2 2021; Phase I preliminary data announced 2/3/2021; Phase I dosed October 2020; FDA clearance for Phase I trial received September 2020, recruiment expected to begin September 2020; Pre-clinical results released September 2020; Data from ongoing animal challenge study released October and November 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04563702
Bharat Biotech International Limited
BBV154; adenovirus vectored, intranasal vaccine
stage-1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I began March 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04751682
Tetherex Pharmaceuticals Corporation
Adneviral vector vaccine, (SC-Ad6-1)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I expected to begin June 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04839042
Institut Pasteur/ TheraVectys
Intranasal lentiviral vector vaccine
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical results published December 2020; Animal study results released July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Valo Therapeutics Ltd/ ImmunoScape
Adenovirus-based + HLA-matched peptides (Pan-Corona)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
iosBIO (formerly Stabilitech Biopharma Ltd)
Oral Ad5 S; (OraPro-Covid-19)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Helsinki/ University of Eastern Finland/ Rokote Laboratories Finland Ltd
Ad 5 vector for intranasal administration
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Bharat Biotech/ Thomas Jefferson University
Recombinant deactivated rabies virus containing S1; (CoraVax)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical data published October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Massachusetts Eye and Ear/ AveXis, a Novartis Company/ Viralgen/ Aldevron/ Catalent/ Penn Medicine
AAVCOVID, Adeno-associated viral vector (AAV), spike protein
pre-clinical
Funder
Funder
n/a
Gates Foundation
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Pre-clinical results released January 2021; Phase I to begin second half of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
GeoVax / BravoVax/ NIAID/ NIH/ University of Texas Medical Branch
Non-replicating viral vector; MVA encoded VLP
pre-clinical
Funder
Funder
n/a
National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH)
Related use
Related use
n/a
Same platform as vaccine candidates for LASV, EBOV, MARV, HIV
Anticipated Next Steps
Anticipated Next Steps
n/a
Awarded a Small Business Innovative Research (SBIR) grant in January 2021 to support the ongoing design, construction, and preclinical testing in preparation for human clinical trials
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Globe Biotech Limited, Bangladesh
Adenovirus Type 5 Vector
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CanSino Biologics/ Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China
Ad5-nCoV
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I recruitment began end of September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04552366
National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO, Thailand
Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Ankara University
Adenovirus-based
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IDIBAPS- Hospital Clinic, Spain
MVA-S
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Greffex
Non-replicating viral vector; Ad5 S (GREVAX™ platform)
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Centro Nacional Biotecnologia (CNB-CSIC), Spain
Non-replicating viral vector, MVA expressing structural proteins
pre-clinical
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ID Pharma
Sendai virus vector
pre-clinical
Funder
Funder
n/a
Unknown
R